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ABSTRACT 
 
In this study different in vitro models were developed to study the long term and short 
term drug- drug interactions occurring upon oral administration. 
MDCK cells were stably transfected for the simultaneous expression of P-gp and 
CYP3A4 (MMC) as well as MRP2 and CYP3A4 (MMrC). These were characterized by 
using expression and activity studies. Cellular transport study of 200 μM cortisol, was 
performed to determine their combined activity. The study was carried across control, single 
transfected and dual transfected cell lines. Similar studies were also carried out in the 
presence of 50 μM naringin (herb) and 3 μM morphine (drug of abuse). A dual chamber 
model with transfected MDCK on apical and transfected HEPG2 cell line in basal chamber 
was also used to study similar interactions.  
For long term interactions LS180 cells were treated with combinations of HIV 
protease inhibitors (PIs: Lopinavir, Indinavir, Saquinavir and Amprinavir) and mRNA 
expression of efflux transporters and CYP3A4 was quantified. These expression levels were 
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further correlated to PXR levels. Uptake of florescent and radioactive substrates was used to 
study activity of the proteins. Cytotoxicity and ATP assays were used stress markers. 
The MMC and MMrC cell lines were characterized for stable expression of both 
proteins. Decreased Apical-Basolateral transport of cortisol and enhanced metabolite 
formation was observed in dual transfected cells as compared to non-transfected and single-
transfected controls. Transport of cortisol increased fivefold in presence of naringin in MMC 
and threefold in presence of morphine. The dual chamber model showed greater in vitro – in 
vivo correlation to rat model than single chamber models.  
Binary combinations of PIs showed greater induction of efflux proteins (5–15 fold) as 
compared to ternary combinations (1-4 fold) or individual PIs. The altered mRNA expression 
correlated with expression levels of PXR but not CAR. Expression levels also correlated well 
with protein expressions and activity assays. No cytotoxicity or ATP activity was observed.  
These new cell lines can serve as an invaluable model to study drug interactions as they 
incorporate the combined contribution of efflux transporters and CYP3A4. Also use of drug 
combinations can significantly alter their bioavailability and disposition resulting in failure 
during chronic therapy. 
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CHAPTER 1 
INTRODUCTION 
 
Overview 
 The cost of getting an approved drug into the market has gone up considerably 
and is estimated to be close to a billion dollars. This drug discovery to approval process also 
takes decades. The major reason for this is that a pharmaceutical company works on multiple 
lead molecules out of which a majority of them fail. The main cause of this failure is the poor 
absorption, distribution, metabolism, excretion and transport (ADMET) characteristics of the 
drugs which prevent these from being physiologically useful. The industry is constantly on a 
lookout for more streamlined methods of carrying out these ADMET screening of all its lead 
molecules so that only the molecules with least possibility of failure due to pharmacokinetic 
problems go through to the later rounds of clinical trials. But very few highly reliable, low 
cost and high throughput models exist which can be utilized to carry out these studies 
effectively. The industrial work horse still remains Caco-2 cells which are more than three 
decades old and have innumerable problems associated with them. 
Drug-drug interactions can occur when one drug alters the pharmacokinetics or 
Pharmacodynamic of other co-administered drug/drugs. Pharmacodynamic interactions may 
occur due to multiple reasons but in case of pharmacokinetic interactions this is most often a 
result of induction or inhibition of efflux transporters and metabolizing (CYP450) enzymes. 
Long term treatment with medications may lead to induction of certain proteins. Induction of 
certain metabolic enzymes can  result in altered or increased metabolism resulting  in reduced 
presence of active drug  in the system.  Induction of efflux transporters can further result in 
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the decreased absorption and increased excretion of the drugs from the body. These changes 
can eventually affect the pharmacology and toxicology of the drugs. There are systems 
available to study induction potential of a drug for a particular enzyme in isolation. No model 
has been studied yet to see the induction effect of a combination of drugs on multiple 
proteins. 
When two or more drugs that are substrates of a common efflux transporter or a metabolizing 
enzyme are administered together they may also lead to drug–drug interaction. Because of 
the common substrate specificities they often act as competitive inhibitors for the same 
protein. This often results in decreased metabolism or increased absorption resulting in an 
overall increased oral bioavailability of one of the drugs following oral administration. This 
often results in drug toxicities.  The current in vitro  models utilized to study these 
interactions do not express similar levels of enzymes as observed in physiological systems 
and hence the intensity of these interactions are often underestimated. Also there are complex 
interplay that exist between efflux and metabolism in the physiological systems that does not 
exist in the currently prevalent in vitro models. 
Though many of these drug interaction studies are carried out in rodents and other 
animal models, species specific differences have shown  to play a very significant role in the 
eventual outcome. The small differences in homology of these proteins in humans versus 
other vertebrates often  results in significant differences in overall activity of these proteins. 
Even in the case of in vitro models, the origin of the cell line affects the activity of the 
protein and  hence if the proteins are not of human origin, the drug interactions can be over 
or underestimated.  
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Therefore there is a need to develop an effective in vitro cell culture model that could 
improve the estimation of drug interaction that can occur following oral administration. 
Presence of models that express human proteins at physiological levels could be highly 
beneficial in prediction of potential drug interactions and also will be a cost cutting measure 
for the pharmaceutical industry in the screening of potential drug candidates. 
 
                                                  Statement of the Problem 
Multi-drug regimens and corresponding drug-drug interactions cause many adverse 
drug reactions and treatment failures. Therefore, the contemporary drug development process 
places a substantial focus on the generation of data on drug-drug interactions involving each 
new drug entity. Delineation of such drug interactions through clinical pharmacokinetic 
studies involves substantial expenditure and time that are critical in terms of the drug 
development timeline. Human volunteers that participate in such clinical studies are also at 
risk of unknown dangers. If all the required clinical studies are planned and carried out as per 
the traditional protocols, some real and potentially important interactions may be missed 
simply because it is not possible to do each and every needed study due to time constraint 
and cost. In order to address this, scientists involved in drug development in the 
pharmaceutical industry, the academic sector and the regulatory agencies have increasingly 
turned to in vitro models as an approach to provide some degree of predictive advance 
information that can guide the planning of clinical studies. 
Specific objective of the proposal is to develop models for assessing drug interactions 
taking place at intestine and liver, the two major sites of drug interactions in oral drug 
delivery. Efflux transporters (e.g. P-gp, and MRPs) and metabolizing enzymes (CYP 450 
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class of enzymes) expressed in these organs are the major mechanisms behind many of the 
known drug interactions. Several in vitro models such as Caco-2, MDCK for small intestine 
and hepatocytes and microsomes for liver have been extensively used for assessing drug 
interactions mediated by efflux proteins and metabolizing enzymes. But limited or lack of 
constitutive expression of efflux transporters and metabolizing enzymes of interest has been 
recognized as the inherent weakness of these models. Hence, we propose to develop in vitro 
models in order to overcome some of these deficiencies. 
One approach to achieve this objective is to modify aforementioned cell lines such 
that they express higher levels of proteins of interest. We, therefore, propose to develop 
MDCK cells expressing higher levels of efflux transporters and metabolizing enzymes. 
However, this project focuses not on a single protein or specific cell line but on a specific 
combination of efflux transporters and metabolizing enzymes that are known to be involved 
in drug interactions. For example, P-glycoprotein and CYP3A4 act in a concerted manner to 
limit the oral absorption of many drugs. While it was clearly established that both of them are 
responsible for this phenomenon, exact contribution of each protein is not clear. By knowing 
this information, it will be possible to predict and avoid imminent drug interactions with 
much more accuracy. 
Moreover, we propose to extend the concept to combination such as MRP2/CYP3A4 for 
which no information is available whatsoever.  
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Objective  
With this back ground the objective of this dissertation are: 
 To develop and characterize a modified MDCK cell line stably expressing metabolizing 
enzyme CYP3A4 and efflux protein (P-glycoprotein) and HEPG2 cell line stably 
expressing CYP3A4.  
 To develop and characterize a modified MDCK cell line stably expressing metabolizing 
enzyme CYP3A4 and efflux protein (MRP2) 
   To develop and characterize a modified HEPG2 cell line stably expressing CYP3A4. 
  To use MDCK-MDR1-CYP3A4 cell lines as a models for evaluating short term drug-
drug of abuse  interactions (Morphine on cortisol) and drug-herb interaction (Naringin on 
cortisol) 
 To screen a previously unknown substrate (gatifloxacin) for its potential interaction with 
efflux transporters using transfected MDCK cell lines. 
  To establish an in vitro model to predict the first pass effect in oral drug delivery by 
combining specific model cell. The MDCK cell line (as a model of intestine) will be 
plated in apical chamber and HEPG2 cell line (as a model of liver) in the basal chamber 
of a Transwell™ based cell culture system. 
 To screen protease inhibitor combinations for their potential to induce efflux transporters 
and metabolizing enzymes in model intestinal cell line LS-180 cells.  
The basic experimental design can be explained using the following flow chart: 
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Scheme 1: Methodology used for development of new models 
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CHAPTER 2 
LITERATURE REVIEW 
 
This chapter gives an insight into the various in vitro cell culture models that have 
been studied over time for oral drug delivery. It also discusses in detail about the various 
barriers that a drug is subjected to when it is administered orally and strategies that have been 
investigated incorporate these barriers within the in vitro cell culture models. This section 
would also facilitate understanding of the research goals and findings presented in the 
subsequent sections.  
In industrial or an academic research setting, pharmaceutical drug development often 
requires determination of intestinal permeability, a key parameter to asses oral bioavailability 
Figure 1. Events following administration of solid oral dosage form: 
Importance of intestinal epithelia in overall bioavailability of drug. 
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potential of a drug candidate (Figure 1). Specialized function of epithelial cells lining the 
intestinal mucosa coupled with high expression of metabolizing enzymes can significantly 
limit oral drug absorption.  
A lead molecule can fail phase 1clinical trial due to poor oral bioavailability. 
Absorption through the intestinal membrane is the major rate limiting factor for oral 
absorption. In vitro cell culture models have been frequently employed to evaluate intestinal 
membrane permeability. Caco-2 has been cell line widely recognized due to its inherent 
simplicity and high correlation with in vivo oral bioavailability. Caco-2 has been the work 
horse for both industrial and academic research for in vitro permeability studies. Human 
colon adenocarcinoma derived cell line Caco-2 when cultured on a semi-permeable 
membrane, differentiate into an epithelial barrier with high functional, morphological and 
biochemical properties similar to the intestine
1-3
. The fully differentiated cell line has been 
successful in predicting oral bioavailability of several drug candidates
4-5
. Caco-2 often is 
considered as the major in vitro cell line not only for the mechanistic studies but also as a 
preclinical absorption screening assay
6-7
.  
Caco-2 although exhibits high efficiency and correlativity, it has significant 
drawbacks. This cell line takes 21 days to fully differentiate and characterize and hence is not 
an ideal cell line for high throughput drug screening. With major advancements in molecular 
modeling and QSAR the number of lead molecules moving forward for preclinical trials has 
increased significantly. Caco-2 has a long growth period i.e. 21 days, rigid feeding 
requirements and prone to contamination, which render it somewhat problematic for in vitro 
testing
8
. Even though some proprietary techniques have been applied to effectively shorten 
the differentiation period for Caco-2 but the added cost reduces its attractiveness
9
. Hence a 
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lot of in vitro pharmacokinetic and drug delivery scientists have pointed their attention 
towards developing other faster growing cell culture models for in-vitro oral absorption 
screening. A faster growing cell line would not only reduce the time and effort of these 
screening studies but also help reduce maintenance costs. 
MDCK (Madin-Darby canine kidney) cells are well characterized cell line for transport study 
across the distal epithelium of the kidney. It is also used to study cell growth regulation and 
metabolism in kidney
10-12
.  When grown on a semi-permeable membrane these cells also 
exhibit similar epithelial morphology and junction characteristics as Caco-2 cells. Papp 
(apparent permeability) values for for several compounds have been found to be similar to 
that observed in Caco-2 cells
13-14
. Hence MDCK cells can be considered to be an attractive 
alternative to Caco-2 cells. Genetically modified form of MDCK cells MDCK-MDR1 
MDCK-MRP2 etc. are being developed to not only provide better correlation to intestinal 
transport but also to provide high throughput methods not easily possible with Caco-2. 
In this chapter we will present in greater detail why the MDCK cells and other 
intestinal cell culture models are better suited for modeling intestinal transport than Caco-2 
cells 
 
Factors Affecting Drug Absorption through Intestine 
For an in vitro model to better correlate with a physiological membrane barrier, it 
should also replicate the physiological, physiochemical and formulation factors governing 
transport across the barrier. To decide upon the criterion for selection of an optimal cell line 
to represent intestinal drug transport we need to know these factors that affect the movement 
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of molecules across intestinal epithelia. Table 1 gives a brief overview of factors affecting 
oral absorption 
 
 
Table 1 Factors affecting drug absorption from gastrointestinal tract (GIT) 
Physiological factors Physio-chemical factors Formulation Factors 
 
Physiology of GIT 
1. pH of various segments  
2. Esophageal transit time 
3. Esophageal motility 
4. Presence or absence of 
food  
 
1. Drug stability in GI 
fluid 
2. Ionization constant  
3. Lipophilicity of the 
drug 
4. Drug solubility 
5. Crystal properties 
6. Dissolution rate 
7. Salt form  
8. Protein binding  
9. Complex formation 
10. Adsorption 
1. Solutions  
2. Suspensions  
3. Capsules 
4. Tablets   
5. Coated tablets  
 
 
Mode of transport across GI 
track 
1. Passive diffusion 
 Paracellular 
transport 
 Transcellular 
transport 
 Facilitated diffusion 
2. Active transport 
3. Vesicular transport  
 Endocytosis 
 Pinocytosis 
4. Metabolism 
 
  
 
Miscellaneous 
1. Smoking  
2. Alcohol consumption 
3. Other drug use 
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 Intestinal absorption of drugs is an intricate process involving interplay between many 
factors such as a) physiological factors, b) physico-chemical factors and c) formulation 
factors which are noted in table 1 
15-16
 
 Whether A drug is undergoing passive diffusion or carrier mediated influx/efflux or is being 
metabolized during its transit through the GIT can be evaluated using the proper cell line. 
 
Mode of Transport of Drugs through the GI Tract 
Plasma membrane of an epithelial cell layer of the GIT consists of phospholipid 
bilayer membrane and cholesterol as its major constituents. Drug molecules must navigate 
through this lipoidal membrane to enter into systemic circulation.  pH of GI tract varies 
across the GIT, with stomach pH from 1-3, duodenum pH from 6.0 to 6.5 and large intestine 
pH from 5.5-7.0. pH on the site of absorption dictates whether orally administered drug 
remains either in ionized or unionized form. The unionized form tends to easily pass through 
the lipoidal membrane compared to ionized form which can in general be explained by pH 
partition hypothesis. Low molecular weight drugs can diffuse through the GI membrane at a 
faster rate than high molecular weight compounds. Transport of drugs across the 
gastrointestinal epithelia can be mediated by either active or passive processes as shown in 
Figure 2.  
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Figure 2. Mode of drug transport across Cell Membrane 
 
Passive Diffusion  
Passive transport involves simple diffusion of drug molecules in the direction of 
concentration gradient. The rate at which a particular compound diffuses across a membrane 
is governed by Fick’s law which is represented by Eq. 1. 
  
  
 
              
 
 ……………………………………………  Eq. (1) 
  
  
 = Diffusion Rate 
D= Diffusion Coefficient 
A= Cross sectional surface area of the membrane across which drug transfer occurs 
K= oil/water partition coefficient for the drug. 
h = thickness of the membrane through which diffusion occurs 
(C1- C2) = drug concentration gradient between donor and receiver compartments 
Passive diffusion can occur by three mechanisms: 
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 Paracellular transport: In this process drug molecules translocate through water 
filled channels/pores present in junctions. The gastrointestinal epithelia have very 
tightly bound cells in epithelia also known as tight junctions (TJ). TJs are present in 
both the apical and basolateral surface of GIT further reduce the penetration capacity 
of hydrophilic drug substances. These water filled pores constitute only 0.01-0.1% of 
the total intestinal surface area resulting in incomplete absorption. Generally only low 
molecular weight hydrophilic compounds are absorbed into systemic circulation 
through the paracellular route.   
 Transcellular transport: This mechanism represent the major pathway of drug 
diffusion across intestinal epithelial cells. Generally lipophilic drugs having higher 
solubility into the lipid bilayer of plasma membrane are primarily absorbed by this 
process. Theoretical models of transcellular transport suggest the importance of size, 
charge and lipophilicity on membrane permeability. 
 Facilitated diffusion process: As the name suggests it is a simple diffusion process 
which is facilitated by the presence of transporter proteins on the cell membrane. 
Since it is a passive process molecules are transported in the direction of 
concentration gradient and do not require energy such as ATP for transport. 
Cyanocobalamin (Vitamin B12) is primarily transported by this process. 
 
Active transport 
It is a mechanism in which drug is up taken by the membrane bound proteins and then 
transported with the help of energy across a concentration gradient. The energy is primarily 
derived by the breakdown of ATP molecules. This energy is either directly obtained from 
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hydrolysis of ATP or in the form of stored energy. Na
+
/K
+
 ATPases, H
+
/K
+
 ATPase, Ca 
2+
 
ATPases and ABC transporters belong to the first category of active transporters where the 
energy is directly obtained from hydrolysis of ATP is utilized. Transport systems such as 
peptides
17
, vitamins
18
, amino acids, and sugars 
19
 have been identified on the GI tract. These 
transporters are saturable at high drug concentrations. 
Active transporters are broadly classified into two categories on the basis of their direction of 
transport, a) influx transporters and b) efflux transporters. The influx transporters transport 
the drug from outside the cell into the cytoplasm whereas the efflux transporters pump 
molecules out of cytoplasm into extracellular fluid. 
Major influx and efflux transporters that have been targeted to facilitate intestinal drug 
transport are described in the following section. 
 
Transporters on GIT 
Influx Transporters: 
Amino acid transporters 
These transporters aid in the movement of amino acids from GIT into systemic 
circulation as well as subsequent uptake into tissues/cells. It represents one of the most 
abundant transporter class in the body with expression in all living cells. Amino acid 
transporters can be classified on the basis of charge, sodium dependency and substrate 
specificity
20
. The y+ and L type sodium independent amino acid transporters are present on 
GI epithelium. The y+ type helps in transporting cationic amino acids whereas L type 
translocates large neutral amino acids. L type transporters also ferry many branched and 
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aromatic amino acids across the GIT. Broad substrate specificity of these transport systems 
also allows absorption of a large number of amino acid-related compound i.e., melphalan
21
. 
Sodium dependent amino acid transporters need to bind to sodium ions prior to the 
movement of amino acids. Binding with Na+ and substrate causes the transport protein to 
undergo a specific conformational change resulting in the movement of sodium and amino 
acid in cytoplasm. Amino acid transporters can be further classified based on the nature of 
amino acid being transported into B type (transports dipolar amino acids having an amino 
acid group in α-position), B 0, + type (transports all dipolar amino acids including with an 
amino acid group α-position as well as basic amino acids), IMINO (transports imino group 
containing amino acids) and β type (transports all β amino acids). Examples of drugs 
transported by sodium-dependent amino acids transporter are gabapentin and L-α-
methyldopa
22-23
. 
Bile acid transporter 
Bile acid transporters are mainly localized on the hepatocyte plasma membrane and 
ileal brush border membrane in mammals.  Bile acids display steroid like chemistry and are 
derived from cholesterol metabolism. These transporters are mainly responsible for 
absorption of fats from small intestine.  Bile acids are secreted in the small intestine 
following food ingestion. These secretions augment the process of digestion. Secreted bile 
acids are again reabsorbed by both active and passive mechanisms. In the terminal ileum 
these compounds are actively taken up into the blood stream from where bile acids re-
circulate into the liver via the portal vein. The entire process is called as enterohepatic 
recirculation 
24
. These transporters are described as sodium-dependent sodium taurocholate 
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co transporting polypeptide (NTCP), organic anion transporting polypeptides (OATP-C, 
OATP8, and OATP-A) and apical sodium-dependent bile acid transporter (ASBT) and are 
ATP-dependent [bile salt export pump (BSEP)]
25
.  
 
Monocarboxylic acid transporters 
Lactic and pyruvic acids belong to the category of monocarboxylic acids. In most 
cells glycolysis is the major pathway of ATP production. One molecule of glucose undergoes 
biochemical reaction to generate two molecules of lactic acid which is continuously pumped 
out to shift the equilibrium forward and hence to maintain a high level of glycolysis. Any 
deficiency in this process can lead to accumulation of lactic acid resulting in pH reduction, 
discomfort and even inhibition of glycolysis. Tissues like brain, heart, and red skeletal 
muscle can oxidize lactic acid, thereby needing supply of more lactic acid inside cell 
compartment. Proton coupled monocarboxylic acid transporters are key in the movement of 
lactic acid into and out of cells
26
. Approximately nine subtypes of monocarboxylic acid 
transporters (MCT1-9) have been reported in mammals. Examples of drugs transported by 
this system are phenthicillin, nateglinide
27
, ceftibuten, carindacillin and carbenicillin
28
. 
 
Peptide transport systems 
Peptide transporters are being pursued as carriers for the transport of many drugs and 
prodrugs because of their high capacity and broad substrate specificity. These transporters 
are present mainly on brush border membrane of small intestine and are responsible
 
for the 
translocation of small peptides generally containing two or three
 
amino acids, across 
epithelial cell membrane
29
. Two peptide transporters, PepT1 and PepT2 have been identified 
17 
 
and functionally characterized in mammals
12
. Expression levels of PepT1 have been reported 
to be much higher in small intestine relative to kidney whereas PepT2 is expressed only in 
kidney
30
. Dipeptides and tripeptides are reported to be good substrates for PepT1. Single free 
amino acids and peptides with more than three amino acids have low affinity for these 
transporters, PepT1 transporter is driven by protons generated from Na 
+
/ H 
+
 exchanger 
present also on intestinal brush boarder membrane. Recently oral delivery of drugs and 
prodrugs utilizing intestinal PepT1 has gained a lot of attention.  
 
Nucleoside transporters 
Nucleoside analogues do not readily cross the membranes due to polar nature. Hence 
these compounds are highly dependent on transport proteins known as nucleoside 
transporters. Based on sodium dependency these proteins are classified into two types: a) 
sodium dependent and b) sodium independent. Concentrative nucleoside transporter 
belonging to CNT family is the major transporter of sodium dependent class. hCNT’s can be 
further classified into hCNT1, hCNT2 and hCNT3
31
.  hCNT1, hCNT2 preferentially 
transport pyrimidines and purines respectively while hCNT3 transports both purines and 
pyrimidines.  Equilibrative nucleoside transporter (ENT) family belongs to the sodium 
independent class of nucleoside transporters. These are further classified into ENT1 and 
ENT2. The transport systems facilitate the transport of purine/pyrimidine analogues down 
their concentration gradient
32
. These transporters play a vital role in the oral absorption of 
many nucleoside polar anticancer
 
drugs like zidovudine, gemcitabine, zalcitabin, fludarbine 
and 5-fluorouridine
22, 33
. 
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Efflux Transporters: 
 ATP binding cassette (ABC) efflux proteins or pumps are present in all living species 
with a relatively conserved structure that constitutes a conserved ABC and trans-membrane 
domains
34-35
. Efflux pumps are responsible for imparting drug resistance by actively 
effluxing out drugs molecules out of cytoplasm. This phenomenon is thus named multiple 
drug resistance or MDR. Efflux proteins are designed to protect the cells from endogenous or 
exogenous toxins. These proteins are expressed largely on secretary, absorptive organs and 
blood tissue barriers
36-37
. The major ABC transporters are P-glycoprotein (P-
gp/MDR1/ABCB1), multidrug resistance associated protein 2(MRP2/ABCC2/cMOAT) and 
breast cancer resistance protein (BCRP/ABCG2/MXR i.e. mitoxantrone resistance protein)
38-
40
. 
 
P-glycoprotein (P-gp) 
It was first characterized in the 1970s as the ATP dependent transporter responsible 
for emergence of resistance from chemotherapeutic agents by effluxing them out of the 
cancer cells
41-42
. It is an integral membrane protein having two homologous halves. Each half 
contains one hydrophobic domain with six transmembrane segments and one hydrophilic 
nucleotide binding domain or ATP binding domain (Figure 3). The two halves of the protein 
are bound by a short flexible polypeptide linker to form a functionally active 1280 amino 
acid protein. P-gp encoding genes are expressed by hamsters, mice humans and other species. 
A small multigene family encodes this protein, MDR1-3. Rodents express all three classes of 
proteins while only type 1 & 2 are expressed in humans. It is expressed in various human 
tissues including brain, Intestine, kidney, liver, lungs and pancreas
43-44
. 
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Figure 3. Structure and membrane topology of P-gp 
Mammalian P-gp displays approximately 60-65% homology with the gene expressed 
in other species suggesting that the role of the protein in the drug trafficking has been highly 
conserved throughout evolution. With the help of transfection studies it was determined that 
types 1 & 2 are involved in drug efflux where as type 3 is a phosphotidylcholine translocase 
enzyme responsible for the secretion of the phospholipids into bile
45-46
. Evidence gathered so 
far suggests that P-gp interacts with non-polar substrates directly within the lipid bilayer and 
effluxes them out. It may also be binding to the substrate from the cytoplasm and transferring 
it from the inner to the outer leaflet of the bilayer. The mechanism has been schematically 
represented in Figure 4. This should be pointed out though that a clear mechanism for the 
translocation of the drugs by this protein has not yet been established
35, 43
. 
In intestine P-gp is localized in the villus tip of enterocytes in close proximity to the 
lumen
47
. This location is ideal relative to pumping the compounds back into the gut lumen 
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and hence limiting their absorption. Involvement of P-gp in drug efflux was observed in 
Caco-2 cells and then unequivocally established with MDR1 knockout mice
47-49
. 
 
Figure 4. Simplified depiction of P-gp structure and function 
 
The most important feature of P-gp is that it has the ability to efflux a wide variety of 
compounds. Substrates include drugs from various therapeutic classes However all drugs 
within the same class do not undergo same degree of efflux. For example the calcium 
channel antagonist verapamil is a good substrate whereas nifedipine is not
50-51
. 
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Multidrug resistance associated protein MRP-2 
In 1992, another type of drug efflux pump causing resistance in cancer cells was 
discovered and classified under the name multidrug resistance-associated protein (MRP)
52
. 
While only two isoforms of P-gp are present in humans, a much greater number of MRPs are 
expressed. At least seven varieties of MRPs so far have been identified i.e., MRP1-7. MRP7 
being the most recent inclusion and hence less is known about its characteristics. The 
remaining six is divided into two sub categories. MRP1, MRP2, MRP3, and MRP6 belong to 
the category of MRPs having an extra N-terminal domain and MRP4 and 5 belong to a 
category without one. 
Although MRP1 was the first MRP to be recognized as multidrug resistance 
associated protein, biochemical and genetic research had also shown the presence of an 
organic anion transporter in the canalicular membrane of hepatocytes
53-55
. This transporter 
was initially named as canalicular multispecific organic anion transporter or cMOAT which 
was later added to the MRP series in the form of MRP2. 
The structure of MRP2 resembles that of P-gp. It has the conserved core of 12 
transmembrane domains divided into two similar halves, each half containing six helices and 
one nucleotide binding domain or ATP binding domain (Figure 5). MRP2 like MRP1, 3 and 
6 also contains an additional amino terminal domain having five transmembrane helices
56
. 
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Their substrate specificity and further characterization in mice was done in cMOAT knock 
down mice. These mice show similar etiology to human disease i.e., Dubin–Johnson 
syndrome
56-57
.  Due to a high degree of homology between MRP2 and MRP1 it is expected 
that they both would show similar substrate specificity. Introduction of MRP2 cDNA into 
cultured liver HepG2 cells enhanced their sensitivity to cisplatin, vincristine, doxorubicin, 
and the camptothecin derivatives
58
 
 
Figure 5 Structure and Topology of MRP2 and BCRP 
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Breast Cancer Resistance Protein (BCRP) 
BCRP was initially identified in a breast cancer cell line that strangely showed drug 
resistance even in the presence verapamil a potent P-gp inhibitor
59
. This cell line was first 
cloned in 1998 by Doyle et al. The drug-resistant cell line also known as MCF-7/AdrVp 
showed an ATP-dependent efflux of anthracyclines even though known multidrug 
transporters, such as P-gp or MRP1-2 was absent. Although this protein is not over expressed 
in breast cancer, but as it was first isolated from the breast cancer cell line, hence termed as 
Breast Cancer Resistance Protein (BCRP). 
Miyake et al. also identified the same efflux pump in a mitoxantrone-resistant human 
colon carcinoma cell line S1-M1–80 and hence this protein also received the name MXR60. 
BCRP/MXR is the second member of the G subfamily of ABC transporters. It has been 
recommended by the Human Gene Nomenclature Committee that BCRP should be renamed 
ABCG2. It was also named as ABCP where p stands for placenta, to signify its high levels of 
expression in that tissue. BCRP, MXR and ABCP are all similar protein differing only in one 
or two amino acids in their sequence. Structurally it differs from the other prominent ABC 
transporters. BCRP is a so called half transporter having only six transmembrane helices and 
only one nucleotide binding domain (Figure 5). With the help of low resolution 
crystallography it has been shown that BCRP is formed by two of these protein molecules 
forming a homodimeric structure
61-62
.   
BCRP is one of the major efflux pumps in cancer cell lines due to its high efficiency 
in effluxing out chemotherapeutic agents. Its expression in significant amounts has also been 
observed in other human tissues. Major work on the expression levels of BCRP in various 
human tissues has been done by Doyle and group
63
. The largest amount of BCRP is 
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expressed in the placenta. Its levels of expression in the intestine and liver are also 
significant. It is also expressed in colon, brain, ovary and testis in significant amount.  
A large of number of drugs belonging to different therapeutic classes, like anti-
cancer, antibiotics, anti-hypertensive, and anti-diabetics, belong to the list of BCRP 
substrates. Substrate specificity of BCRP has been a subject of many reviews
64-65
. Anti-
cancer agents exported by BCRP are mitoxantrone, topotecan, and anthracyclines i.e., 
daunorubicin and doxorubicin
63
. Nucleoside analogs like zidovudine and lamivudine also act 
as BCRP substrates
66-67
. Prazosin
68
 and the tyrosine kinase inhibitors CI1033 and STI571 
69-
70
 are also BCRP substrates. 
Overall BCRP shows a wide range of substrate specificity. Even though BCRP 
substrate recognition overlaps with P-gp and MRP2 yet it has its own characteristic substrate 
requirements, distinguishing it from the former two. P-gp has a preference for uncharged 
hydrophobic compounds as well as weakly basic compounds
71
. BCRP on the other hand can 
efflux both hydrophobic and hydrophilic substrates irrespective of whether these compounds 
are conjugated or un-conjugated
63-64, 71
. MRP2 and BCRP also share substrates but with 
different affinity. MRP2 can efflux out almost all glutathione, sulfate, and glucuronate 
conjugates
72
, while BCRP can transport more sulfate than glucuronide conjugates. Moreover 
it has not been experimentally shown to transport glutathione conjugates. 
Due to high levels of expression in the small intestine and gut as well as its broad 
substrate specificity, BCRP is considered as an significant barrier to oral drug absorption of 
the drugs. 
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Major Metabolizing Enzymes on GIT 
Table 2. Levels of major CYP enzyme expressions depending on their location on GIT 
(5 being highest 1 being lowest) 
 
The GIT expresses several metabolizing enzymes responsible for drug metabolism 
but their levels vary considerably from one segment to another. Cytochrome P450 is a family 
of major metabolizing enzymes. CYP3A4 constitutes the majority among all the CYP 
enzymes and makes up to about 70% of all CYP enzymes. The expression of CYP3A4 like 
all other CYPs varies from location to location in the GIT. In the duodenum and proximal 
intestine it constitutes the majority but in the distal part it is surpassed by CYP3A5
73
. This 
trend is summarized in Table 2 based on the values presented by Finnstrom and group
74
. 
Levels of enzyme expression have been ranked from 1 to 5 with 5 being the highest 
expression and 1 the lowest. 
CYP3A4 is highly expressed in the liver and this hepatic expression also plays a 
critical role in the overall oral bioavailability of the drug due to first pass metabolism. 
Recently studies are being undertaken to examine whether these metabolizing enzymes work 
in conjunction with the efflux proteins. It is hypothesized that the metabolizing enzymes and 
 Stomach Duodenum Ascending 
colon 
Transverse 
colon 
Descending 
colon 
CYP1B1 5 1 4 1 1 
CYP2E1 3 2 2 1 3 
CYP3A4 3 4 2 1 2 
CYP3A5 4 5 4 3 2 
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the efflux proteins may together play a synergistic role in limiting the overall bioavailability 
of therapeutic agents 
Cell Culture-Based Permeability-Screening Models 
A large number of cell monolayers derived from various organs and various species 
have been developed to represent in vivo intestinal epithelium in humans. These models exist 
of immortalized cells generally derived from tumor cells. These cells grow very rapidly, form 
confluent monolayers and exhibit many physiologic and biochemical properties of 
differentiated epithelial cells. Cell culture models can be employed for the rapid estimation of 
the intestinal permeability of drug candidates at low cost, in a rapid manner and without 
involving any animal or human tissues. 
 
Properties of an Ideal Intestinal Model 
To be considered as an effective cell culture model it should fulfill the following 
requirements 
1. should resemble in surface morphology and topology. 
2. should be fast growing, have low cost of maintenance, and be amenable for rapid 
screening. 
3. should express all the proteins expressed by the target organ in similar proportions. 
4. should show good correlation with intestinal permeability for compounds transported 
both by paracellular and transcellular routes. 
5. should be functional in the pH range prevailing in the intestine. 
6. should have low passage to passage variability. 
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MDCK and Other Cells as Models for Intestinal Absorption and Drug Interactions 
Table 3. Spearman’s Rank Correlation Coefficients (rs). Based on the values by Irvine 
et. al. 
Comparison  rs 
Caco-2 Papp versus MDCK Papp  0.93 
Human absorption versus MDCK Papp  0.58 
Human absorption versus Caco-2 Papp  0.54 
 
 
MDCK Cells 
Madin-Darby canine kidney (MDCK) cells is a dog renal epithelia derived cell line. 
In 1989 for the first time MDCK was discussed as a model to delineate the intestinal 
transport kinetics of a drug
13
. MDCK cells also differentiate into columnar epithelial cells 
and form tight junctions similar to Caco-2 cells however in a lesser time (3 days as compared 
to 21 days for Caco-2) when cultured on semi permeable membranes. In 1999 Irvine et al. 
examined MDCK cells as a model for evaluating the membrane permeability properties of 
lead compounds in early drug discovery stages
8
. In this study MDCK cells were grown on 
Transwell
©
COL membrane culture inserts at elevated cell counts for 3 days. Papp values for 
fifty five drug molecules with known human values were measured in MDCK with Caco-2 as 
a comparative cell line. Papp values obtained using MDCK cells correlated well with both 
Caco-2 cells and human oral bioavailability as represented in Figure 6. These correlations 
between MDCK and Caco-2 have been summarized in Table 3 using the values given by 
Irvine and group
8
. Since Caco-2 (derived from human colon carcinoma cells) and MDCK 
(derived from dog kidney cells) are derived from different organs of different species it is to 
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be expected that that the expression level of various transporters will differ between the two 
cell lines.  
 
Figure 6. Correlation of MDCK and Caco-2 apparent permeability (Papp) values for 
(♦) passive diffusion compounds; (Δ) active transport compounds; (O) efflux substrates 
(adapted from Irvine et al., 1999, with permission from Wiley InterScience® 
 
Presence of transporters on MDCK cell lines and their quantitative expression were 
compared with Caco-2
75-76
. This report suggested that basolateral transport of the two cell 
lines differ significantly due to difference in transport mechanisms. Peptide transporter on 
MDCK cell liner was functionally five times less active than in Caco-2 cells. Scaling factors 
may be necessary for calculating the pharmacokinetic parameters by taking this functional 
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disparity into account. Expression of monocarboxylic acid transporters on MDCK cell line 
also could be correlated with intestinal carrier mediated transport. The presence of efflux 
pump i.e., P-glycoprotein was also significant comparable to Caco-2. MDCK cells showed 
these high levels of the transporter expression in 3-5 days post seeding where as Caco-2 
requires 17-21 days and longer (depending on the passage). Large neutral amino acid 
transporters as well as bile acid transporters were also expressed albeit in insignificant 
amounts and hence this cell line may not be suitable for estimating the effects of these 
transport systems on drug delivery. One of the key advantages in the favor of MDCK cells as 
supposed to Caco-2 cells is rapid culture time (only 3 days vs. 3 weeks). A shorter growth 
and differentiation time translates into faster results and reduced cost. MDCK cell line 
appears to be a more robust cell line relative to Caco-2 and require less rigorous feeding 
schedule over a short incubation period.   
 
Transfected MDCK cell lines 
A number of influx and efflux transporters are present on GI epithelium. Most of 
these proteins are expressed in significant quantities in Caco-2 which makes it a dominant 
cell line. To overcome this shortcoming, genetically modified cell lines are being developed 
in which the plasmids containing genetic code for influx and efflux transporters transfected 
(mainly MDCK) are resulting in elevated expressions of the transporters in this cell line. For 
example MDCK-MDR1 cell line in which the MDCK cell line is transfected with MDR1 
gene resulting in elevated expression of P-gp. Transfected cell lines are suitable for 
investigating the contribution of a transporter to transcellular transport. These transfected 
models add greatly to our knowledge and understanding of substrate specificity for a specific 
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transporter. Information of substrate specificity can be further incorporated into 
computational modeling which may aid in the design of better substrate or inhibitor drug 
molecules to increase the bioavailability
77-79
. Structural requirements for only a few 
transporter systems have been identified like PePT1 
79
 and P-gp
77-78, 80
. However, structure–
transport properties for a many major drug transport systems are still unknown. It is difficult 
to delineate the relative contribution of each transporter to the overall transport of a 
compound. 
The transfected cell lines have already proven their utility in the field of drug 
interactions
81
. Several compounds act as inducers or inhibitors of influx and efflux 
transporters. Hence such interactions may lead to either elevation or reduction in the oral 
bioavailability of a co-administered drug which shares the same transporter mechanism. 
These cell lines have the capability to function as high throughput screening models for the 
estimation of transporter specificity. A large number of compounds can be screened and a 
database can be created for the possible drug-drug interactions. 
The next section describes some of the common MDCK transfected cell lines currently being 
employed as in vitro oral models. 
 
MDCK-MDR1 
MDCK-MDR1 cell line was created in 1997 by Dr. Borst of Netherland Cancer 
Institute, Amsterdam. Human MDR1 gene was transfected into MDCK cells to obtain this 
cell line
82
. These cells have been reported to show greater expression of P-gp. His group also 
showed that the over expressed P-gp in these transfected cells is localized on the apical side 
of polarized cell monolayers
83
. Currently this cell line is being used as a model to study the 
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human P-gp and its role in drug transport in the intestinal mucosa
84-85
. This cell line holds an 
advantage over the conventional Caco-2 cell line that it expresses higher and fairly uniform 
expression of P-gp than Caco-2. Caco-2 cells have been shown to generate highly variable 
expression of P-gp depending on the culture conditions. Caco-2 also requires much longer 
i.e., at least 17 days for P-gp to be functionally active which is a major disadvantage. 
Since the MDCK-MDR1 cells show much higher expression of P-gp it provides better 
estimation of drug efflux and kinetics in the intestine particularly with P-gp substrate 
molecules. 
 
MDCK-MRP2 
This cell line was also developed by Dr. Borst of Netherland Cancer Institute, 
Amsterdam in 1998
86
. The authors first studied the expression levels of the gene cMOAT for 
MRP2 expression protein in nonpolarized cells. The protein was expressed at a higher level 
in the cytoplasm than on the cell surface. Hence MDCK was considered as the cell line of 
choice. The gene was expressed into MDCK cells with a retrovirus vector. The protein was 
expressed on the apical side of the cells and caused cytoplasmic efflux of vinblastine. 
Mrp2/Abcc2 is substantially expressed in the mucosal membrane of the epithelium in the 
small intestine. It effluxes various drugs back into the jejunum
87-88
. Several studies have been 
undertaken to delineate the possible role of MRP2 in intestinal kinetics.  
 
MDCK-BCRP 
MDCK-BCRP is a stably transfected cell line expressing an excess of breast cancer 
resistance protein. It was prepared by Dr. Alfred Schinkel of the Netherlands Cancer 
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Institute, Amsterdam
89
. Although this protein is mainly responsible for resistance in tumor 
cells, it is present in many normal tissues in significant amounts. The bile canalicular 
membrane of hepatocytes, the luminal membranes of villous epithelial cells in the small 
intestine and colon, and brain capillary endothelial cells are examples of cells and tissues 
where BCRP efflux pump can play a major role, even greater than the MRPs
90
. The 
localization of BCRP in these barriers makes its pharmacological role very significant as it 
can affect the overall bioavailability of a number of drugs and xenobiotics. 
PhIP, a carcinogen in baked food and cigarette smoke acts as a substrate for BCRP. 
The absorption and biliary clearance of PhIP are also altered by Bcrp1 in mice
91
. Its role in 
intestinal absorption can be seen when orally administered GF120918, a P-gp and BCRP 
inhibitor, significantly increases bioavailability of orally administered topotecan in humans
92
. 
Studies showing the interactions of BCRP with steroidal drugs have also been reported
93
. 
Therefore it is necessary to further characterize the role of BCRP in drug efflux and intestinal 
absorption, for which MDCK-BCRP may be considered an appropriate model. 
 
2/4/A1 cells 
Tavelin et al reported in 1999 a cell culture based model, 2/4/A1
94
, a fetal rat 
intestinal cell line. They reported that this cell line provides a better representation of the 
human small intestinal permeability relative to Caco-2 cells especially in the case of passive 
transcellular and paracellular transport. The sigmoidal relationship between fraction absorbed 
and permeability coefficients in 2/4/A, human small intestine and Caco-2 has been 
summarized in Figure 7
94-95
. The relationship between the absorbed fractions of a structurally 
33 
 
diverse set of orally administered drugs and permeability coefficients was better correlated 
with 2/4/A1 cell line as compared to Caco-2. 
This cell line represents an immortalized cell line and forms well differentiated 
monolayers with tight junctions. The cells also express brush border membrane enzymes and 
transporter proteins. Tight junctions in Caco-2 cells are much tighter than the junctions 
actually present in the epithelial cells of human intestine. The more physiologically realistic 
tight junctions 2/4/A1 cells are proposed as a better model to study the transport of passively 
transported compounds through the paracellular route. Transport rate of poorly permeable 
compounds like mannitol and creatinine across 2/4/A1 monolayers has been shown to be 
comparable to human jejunum which is three hundred times faster than Caco-2 cell. Even 
though the efficiency of this cell line needs to be examined further the currently available 
data regarding the cell line suggests that 2/4/A1 cells are better predictors of transport for 
compounds that are absorbed primarily via the paracellular route. 
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Figure 7. Relationship between the absorbed fraction of structurally diverse sets of 
orally administered drugs and permeability coefficients obtained in 2/4/A1 monolayers 
(based on the data by Tavelin et al., 1999, adapted from P.V. Balimane et al. reprinted 
by permission from Elsevier). Sigmoidal relationships were obtained between the 
fraction absorbed and the permeability coefficient for all the models: (♦) 2/4/A1, (o) 
Caco-2, (Δ) in vivo perfusions of human jejunum. 
 
 TC-7 cells 
TC-7 cells are a subclone derived from the parental Caco-2 cells. A comprehensive 
comparison between the permeability characteristics of TC-7 with parental Caco-2 cells has 
been reported
96-97
. The TC-7 clones have been reported to show similar cell morphology to 
Caco-2 cells. Brush-border membrane and microvilli are present on TC-7 cells also. These 
cells form tight junctions similar to Caco-2. The permeability values of passively and 
transcellularly absorbed compounds across TC-7 cells correlates well with Caco-2 cells and 
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oral absorption in humans TC-7 cells carry an advantage over the Caco-2 is that these cells 
express higher levels of CYP3A4 enzyme which is highly present in the intestine but is 
hardly expressed in Caco-2. Since TC-7 cells are similar to Caco-2 in morphological, 
biochemical and drug permeability properties, the cells appear to be a good alternative to 
Caco-2 cells in representing intestinal drug permeability studies
98
.  
 
 HT-29 cells 
In 1972, Fogh
99
 worked on developing various cell lines from human colonic 
carcinoma. Various cell types were isolated and cultured out of which the HT-29 cell line 
was able to undergo differentiation. This cell line also exhibited a phenotype similar to 
enterocytes when grown in glucose-free medium
100-101
. HT29-H cells are goblet cells which 
can produce mucin molecules leading to the formation of mucus layer similar to which is 
present in human intestinal epithelia. At late confluence, HT29 cells appear to form a dense 
mucus gel with multiple mucus buds on the apical surface. It was experimentally shown that 
the mucus produced by the human goblet cell monolayers acted as a significant barrier to 
testosterone transport
102
. This mucus layer can also act as a barrier to drug absorption due to 
resistance from the unstirred water layer. It can also act by stabilizing the interactions 
between the drug molecules being diffused and the components of the mucus.  
Factors affecting drug transport across the mucus barrier have been studied using this 
cell line. Lipophilicity was shown to be the major factor affecting transport across the mucus 
layer with molecular net charge and size playing a role in limiting the transport
103-104
.  
To further understand the role of mucus on drug transport, HT29-MTX, a subclone model 
has been developed. This cell line has been derived from the parent cell line HT29 by 
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growing cells for 6 months in a medium containing 1 µM methotrexate. This makes the cells 
gain the morphological and mucin producing characteristics of goblet cells
105
.  
Even though such a cell line has the added advantage of mucus protection but it does 
not express sufficient amount of transporters to properly delineate carrier mediated transport. 
This mucus layer is also not very stable and may be removed by the washing steps. Table 4 
summarizes the advantages and disadvantages of each cell line 
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Table 4. Summary of the various cell lines used as intestinal models 
Name of cell line Advantages Disadvantages Ref 
Caco-2 cell 
monolayers 
1. well developed and 
characterized cell line 
2. displays all the 
mechanisms for drug 
transport 
3. mechanistic evaluation 
of transport possible 
4. topographical 
physiology resemble 
intestinal epithelia 
1. slow growth and long time 
to fully differentiate and 
characterize (21 days) 
2. not ideal for high 
throughput assays 
3. has rigid feeding 
requirements 
4. prone to contamination 
5. Forms very tight junctions 
and hence not the best 
model for correlating 
paracellular transport 
6. expression of several 
efflux proteins may not be 
suitable cell line to isolate 
the effect of single 
transporter  
7. lower expression of 
metabolizing enzymes 
relative to human  
intestine 
8. concentration of efflux 
transporters appear to vary 
from lab to lab.   
4-14 
MDCK cell line 1. well developed and 
characterized cell line 
2. short growth period of 
3-5 days 
3. excellent model for 
high throughput 
screening 
4. less rigid feeding 
requirements 
5. lower chances of 
contamination due to 
fast growth period 
6. resembles drug 
transport with both 
Caco-2 and intestine 
7. ideal cell line for 
transfection purposes 
 
1. is a canine cell line so the 
species difference needs to 
be taken into account 
2. a kidney derived cell line 
so the organ variability 
also decides the type and 
quantity of transporters 
expressed. 
3. low expression of all the 
major efflux pumps. 
4. CYP3A5 is expressed in 
large amounts whereas 
CYP3A4 expression is 
less 
8, 13, 
75-76 
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Table 4. Continued..... 
Name of cell line Advantages Disadvantages Ref 
Transfected MDCK 
cell line 
1. has all the advantages 
of the MDCK cell line 
2. interactions with a 
single transporter can 
also be evaluated. 
3. can be used to develop 
computerized 
quantitative structure 
property relationship 
(QSPR) 
4. suitable for high 
throughput screening 
of single transporter 
based drug drug 
interactions 
1. disadvantages associated 
with MDCK models based 
on origin still prevail.  
2. effect of background 
transport characteristics 
not known. 
3. more rigid controls 
needed. 
77-93 
HT-29 cell line 1. only cell line available 
expressing mucin 
resembling the mucus 
layer of intestinal 
epithelium. 
2. has a human as well as 
colonic origin. 
1. a slow growing cell line. 
2. expresses less transporters 
than Caco-2 
3. not suitable model for 
carrier mediated transport. 
4. the mucus layer is not 
stable and is susceptible to 
being washed away 
5. does not differentiate well 
in the presence of glucose. 
99-
105 
2/4/A1 cells 1. generates similar tight 
junctions to human 
intestine and arguably 
the best model for 
paracellular transport  
2. expresses most of the 
carrier proteins and 
membrane bound 
enzymes. 
1. levels of protein 
expressions are low.  
2. a medium to low 
throughput screening 
model. 
94-95 
TC-7 cells 1. advantages of Caco-2 
being a sub clone. 
2. Express high levels of 
CYP3A4 as compared 
to Caco-2 and hence 
better represent 
intestinal metabolism. 
1. similar disadvantages as 
Caco-2. 
96-98 
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                                                            CHAPTER 3 
 
SCREENING OF GATIFLOXACIN INTERACTION WITH EFFLUX TRANSPORTERS 
USING TRANSFECTED MDCK CELL LINES: A POSSIBLE MECHANISM FOR DRUG 
RESISTANCE 
 
                                                               Rationale 
Fluoroquinolones are widely prescribed antimicrobials for prophylaxis and treatment 
of various ocular infections. These compounds possess broad spectrum bactericidal activity 
and concentration dependent effect 
106-107, 108a, 109
. Depending on their range of activity, the 
agents are categorized into four different generations. Nalidixic acid was the first quinolone 
to be introduced. Since then, structural modifications have resulted in the development of 
later generations. The second and third generation drugs like ofloxacin and levofloxacin are 
mainly indicated in the treatment of bacterial keratitis 
110-111
. But the development of 
bacterial resistance against these drugs necessitated the introduction of fourth generation 
fluoroquinolones in combating ocular infections. These antibiotics were originally introduced 
for treating systemic infections 
112-113
. 
The fourth generation drug, gatifloxacin is approved for the treatment of acute 
sinusitis, chronic bronchitis, community acquired pneumonia and other respiratory infections. 
Gatifloxacin is a new 6-fluoro-8-methoxyquinolone that is two-
 
to fourfold more active than 
the other quinolones 
114
. It shows increased activity against gram positive and gram negative 
bacteria. Furthermore, the drug also showed activity against atypical pathogens and 
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anaerobic organisms 
115-116
. This expanded microbicidal activity makes it a potent drug in the 
treatment of ocular infections caused primarily by gram positive bacteria. Gatifloxacin 
inhibits both topoisomerase II (DNA Gyrase) and topoisomerase IV. Due to its dual sites of 
action, two genetic mutations are required for the development of bacterial resistance unlike 
other fluoroquinolones which require only single mutation
108, 117
. This mechanism offers 
gatifloxacin an additional path to resist mutation based development of bacterial resistance. 
Its structure is shown in Figure 8. The methyl substituted piperazinyl group at C-7 position 
leads to increased stability, half life of the drug and improved pharmacokinetic and safety 
parameters over other fluoroquinolones. Moreover, absence of halide substitution at the C-8 
position reduces photosensitivity compared to other fluoroquinolones 
118-120
.  
Gatifloxacin has a high intrinsic activity with minimum inhibitory concentration 
(MIC) of 0.1µg/mL against many bacterial species. Despite this expanded activity, the use of 
gatifloxacin in ocular infections is limited by systemic toxicity upon administration. Sub 
therapeutic concentrations in the corneal aqueous humor and iris-ciliary body can result from 
multi drug resistance (MDR) associated efflux pumps. These pumps expel antimicrobial 
agents out of cell, leading to suboptimal eradication of microbes. An escalating dose may 
result in systemic toxicity. Several efflux pumps have been identified in the eye. The ATP 
binding cassette (ABC) transporters derive their energy from the hydrolysis of ATP and 
utilize this energy to transport the drug molecules out of the cell, thus imparting drug 
resistance. Though these transporters are considered as drug-resistant pumps, they are 
expressed in many normal tissues suggesting their role in cellular transport of many 
endogenous substrates and therapeutic agents
121
. Several members of this family i.e. P-
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glycoprotein (P-gp/MDR1/ABCB1), multidrug resistance associated protein 2 
(MRP2/ABCC2/cMOAT) and breast cancer resistance protein (BCRP/ABCG2/MXR) have 
been identified on the rabbit and human cornea 
122-124
. These efflux pumps can act either 
alone or synergistically contributing to multidrug resistance. 
 
Figure 8. Structure of gatifloxacin 
  
Understanding interaction of gatifloxacin with these efflux transporters is important 
to better delineate the mechanism of its acquired resistance which can lead to the 
development of novel strategies to enhance drug bioavailability at target site. This study can 
also aid in reduction of dose volume, further eliminating the chances of systemic toxicity 
from topical gatifloxacin eye drops. 
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Materials and Methods 
Materials 
Gatifloxacin was obtained from Bosche Scientific (New Brunswick, NJ, USA). 
MDCK transfected cell lines expressing P-gp, MRP2 and BCRP were generous gifts from 
Drs. A. Schinkel and P. Borst (Netherlands Cancer Institute, Amsterdam). [
14
C]Erythromycin 
(51.3 mCi/mmol) was obtained from Moravek Biochemicals (Brea, CA, USA). Quinidine 
and MK-571 were obtained from Sigma-Aldrich (St. Louis, MO, USA). Hoechst 33342, Ko-
143, TrypLE™ Express, Dulbecco's modified Eagle's medium (DMEM) and ATP 
determination kit were obtained from Invitrogen (Carlsbad, CA, USA). Fetal Bovine Serum 
(FBS) was purchased from Atlanta biologicals (Lawrenceville, GA, USA). Culture flasks (75 
cm
2
 growth area), 12-well plates (3.8 cm
2
 growth area per well), polyester transwells (pore 
size of 0.4 µm and 12 mm diameter), and 96-well plates (0.32 cm
2
 growth area per well) 
were purchased from Corning Costar Corp. (Cambridge, MA, USA). All other chemicals 
were products of commercial grade and were obtained from Sigma Chemicals (St. Louis, 
MO, USA) and Fisher Scientific. 
  
Cell culture  
Madin-Darby canine kidney (MDCK) cell line is derived from dog renal epithelial 
cells. It is extensively used as a model to study membrane permeation 
125
. The cell line has 
been transfected with human MDR1, MRP2 and BCRP genes to generate MDCK cells over 
expressing P-gp, MRP2 and BCRP respectively 
126-128
. These transfected cell lines have been 
extensively employed to study drug efflux mechanisms 
129-130
. MDCKII-MDR1, MDCK-
MRP2 and MDCK-BCRP cell lines of passage numbers 5-15, 5-15 and 5-10 respectively 
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were used for our studies. Cells were cultured in T-75 flasks at 37
0
C in a humidified 
atmosphere using 5% CO2 and were maintained with DMEM medium supplemented with 
10% fetal bovine serum (heat inactivated), 1% nonessential amino acids, 20 mM HEPES, 29 
mM sodium bicarbonate and 100 µg/mL of penicillin and streptomycin. The medium was 
changed every alternate day. Cells were allowed to reach 80-90% confluence which was 
confirmed with a microscope and then passaged using TrypLE™ Express solution. The cells 
were seeded at a density of 25,000/cm
2
 in 12-well tissue culture-treated plastic plates and 
collagen coated Transwell
®
 inserts and at a density of 10,000/cm
2
 in 96-well plates. These 
cells were then allowed to grow for 5-7 days and used for further studies. 
 
Preparation of drug solutions 
[
14
C] Erythromycin was selected as a model substrate to study MDR1 and MRP2 
mediated efflux 
131-132
 and Hoechst 33342 was employed as a model substrate for BCRP 
mediated efflux 
133
. Uptake of these substrates was quantified in the presence of various 
concentrations of Gatifloxacin (1µM-10mM). Specific inhibitors such as quinidine (75µM), 
MK-571 (100µM) and Ko-143 (10µM) were selected for MDR1, MRP2 and BCRP 
respectively to delineate interaction of efflux pumps with gatifloxacin.  
 
Uptake studies 
Uptake studies were performed in 12-well tissue culture-treated plates with confluent 
cells, usually 5-7 days post seeding. The medium was aspirated from wells and cells were 
washed (3 ×10 min) with 2ml of Dulbecco’s Phosphate-Buffered Saline (DPBS) containing 
130 mM NaCl, 2.5 mM KCl, 7.5 mM Na2HPO4, 1.5 mM KH2PO4, 1 mM CaCl2, 0.5 mM 
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MgSO4, 5 mM glucose, and 20 mM HEPES at pH 7.4. Then 1 mL of drug solutions (each 
containing 0.25 μCi/mL of [14C] Erythromycin) were added to the cells and incubated at 
37
o
C for 30 min. Then, solutions were removed and uptake was terminated with ice-cold stop 
solution (200 mM KCl and 2 mM HEPES). Later, cells were lysed overnight at room 
temperature with 1 mL of 0.1% (v/v) Triton-X in 0.3 N sodium hydroxide solution. Aliquots 
(500µL) of the cell lysate were then added to scintillation vials containing 3 mL of 
scintillation cocktail (Fisher Scientific, Fair Lawn, NJ) and radioactivity was measured with a 
scintillation counter (Model LS-6500; Beckman Counter, Fullerton, CA), which can measure 
[
14
C] compounds with an efficiency of 95%. Uptake in each well was normalized to protein 
content, estimated by the Bio-Rad protein estimation kit using bovine serum albumin as the 
standard.  
 
Accumulation of Hoechst 33342 
 Uptake study with Hoechst 33342 was performed in 96 well plates 5-7 days post 
seeding. The culture medium was removed and cells were washed 3 times with DPBS buffer 
maintained at pH 7.4. Then cells were incubated for 15 min at 37
o
C with 100 µL of Hoechst 
33342 (5µM) alone, in the presence of Ko-143 (10µM) and various concentrations of 
gatifloxacin. Solutions were then removed and uptake process was terminated with ice cold 
stop solution. Later, cells were lysed with 100 µL of 0.1% (v/v) Triton-X in 0.3 N sodium 
hydroxide solution. Intracellular accumulation of the dye was measured with a fluorescence 
spectrophotometer with excitation and emission filters set at 370 and 450nm respectively. 
Uptake in each well was normalized to the protein content. 
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Transport studies 
Transport of [
14
C] Erythromycin was quantified in the presence of varying 
concentrations of gatifloxacin and in the presence of specific inhibitors at pH 7.4 and 37
o
C. 
Transport studies were carried out with cells seeded on 12 well transwell inserts precoated 
with collagen. Five to seven days post seeding, the medium was removed and the cell 
monolayers were washed with DPBS (3 ×10 min). For apical (AP) - basolateral (BL) 
transport, 0.5 mL of test solution was added to the AP side and 1.5 ml of DPBS was added to 
the BL side. For BL-AP transport, 1.5 mL of test solution was placed in BL side and 0.5 mL 
of DPBS was added to the AP side. These transport experiments were conducted for a total 
time period of 3 hours. Samples (100µL) were withdrawn from the receiver chamber at time 
intervals of 15, 30, 45, 60, 90, 120, 150 and 180 min and replaced with the same volume of 
DPBS to maintain sink conditions. To the samples, 3 mL of scintillation cocktail was added 
and radioactivity was measured with a scintillation counter.  
 
Data Analysis 
 [
14
C] Erythromycin accumulated inside the cells or transported across the cell 
monolayers in the presence of various concentrations of gatifloxacin and specific inhibitors 
were calculated according to Eq. 2 
C sample = (CPM sample * C donor) / CPM donor..................................................................Eq. 2 
Where CPM sample and CPM donor denote average values of CPM counts of sample and donor 
(in quadruplicate) respectively; C donor represents the concentration of donor used and C sample  
represents  the concentration of sample. 
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Calculation of Ki and Vmax 
[
14
C] Erythromycin concentration obtained from uptake studies is fitted to Michaelis-Menten 
equation as shown in Eq.3 
V = Vmax * [C] / (Ki + [C])……….................................................................................Eq. 3 
V represents the observed rate of uptake at a concentration [C] and Vmax is the maximum rate 
of uptake and Ki is the apparent inhibition coefficient of the respective efflux pump.  
 
Calculation of Efflux ratios 
Cumulative amounts of radioactive substance transported across the cell monolayers for the 
total time period was calculated using Eq.4 
             t=t-1 
Q = (Cs *Vt) + ∑ (Cs *Vp) ……............................................................................Eq.4 
                         t=0 
 
Where Cs is the amount of radioactive substance transported at a time t, Vp is the volume of 
the sample withdrawn and Vt is the total volume in the receiver chamber.  
Flux value (J) is calculated according to Eq.5 
J = ∆Q / ∆t * A ………………………………………………………………………….Eq.5 
∆Q / ∆t represents the amount of radioactive substance transported per unit time across the 
cell monolayers with a cross sectional area A. 
Permeability (P) value was then calculated according to Eq.6 
P = J / Cdonor    ………………………………………………………….........................Eq.6 
Thus the efflux ratio was calculated from AP-BL and BL-AP permeability studies as shown 
in Eq. 7 
Efflux ratio = BL-AP permeability / AP-BL permeability ………………………….Eq. 7 
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ATP Assay 
The cells were seeded in 96-well plates at a density of 10,000/cm
2
 and allowed to 
reach confluence. 5-7 post seeding, the medium was removed and the cells were washed with 
DPBS (3 × 10 min). The cells were exposed to various concentrations of drug solutions (100 
µL) at 37
o
C for 30 minutes. Later, drug solutions were removed and lysis solution (100 µL) 
was added. The lysate from the cells was then used for quantitative detection of ATP using 
ATP Determination Kit (Molecular Probes, Invitrogen). ATP solution (5 mM) available in 
the kit served as a control and ATP inhibitors such as ouabain (1 mM), sodium azide (1 mM)  
and 2,4-DNP (1 mM) served as positive inhibitors. Luminescence was then measured using a 
microtiter plate reader (SpectraFluor Plus; Maennedorf, Switzerland) and it was normalized 
to protein count, estimated by the Bio-Rad protein estimation kit using bovine serum albumin 
as the standard. 
 
Statistical Analysis 
All the experiments were conducted at least in quadruplicate (n = 4), and results are 
expressed as mean ± the standard deviation (SD). Statistical comparison of mean values was 
performed with one-way analysis of variance (ANOVA) or a Student’s t test (Graph Pad 
INSTAT, version 3.1). A P-value of <0.05 was considered to be statistically significant. 
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Results 
Uptake of [
14
C] erythromycin in the presence of 75 µM quinidine and 2.5 mM 
gatifloxacin in MDCKII-MDR1 cells 
[
14
C] Erythromycin uptake was performed in the presence of 75 µM quinidine and 2.5 
mM gatifloxacin. Uptake of [
14
C] erythromycin was higher by 107% and 67% in the 
presence of 75 µM quinidine and 2.5mM gatifloxacin respectively (Figure 9). 
 
 
Figure 9. Uptake of [14C] erythromycin (0.25 µCi/mL, 51.3 mCi/mmol) in MDCKII-
MDR1 cell monolayers in the presence of 75 µM quinidine and 2.5 mM gatifloxacin. 
*Indicates P < 0.05. Values represent mean ± standard deviation (n =4) 
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Uptake of [
14
C] erythromycin in the presence of 100 µM MK571 and 2.5 mM 
gatifloxacin in MDCK-MRP2 cells 
[
14
C] Erythromycin uptake was performed in the presence of 100 µM MK571 and 
2.5mM gatifloxacin. Uptake of [
14
C] erythromycin was significantly higher by 177% and 
164% in the presence of 100 µM MK571 and 2.5mM gatifloxacin respectively (Figure 10). 
 
Figure 10. Uptake of [14C] erythromycin (0.25 µCi/mL, 51.3 mCi/mmol) in MDCK-
MRP2 cell monolayers in the presence of 100 µM MK-571 and 2.5 mM gatifloxacin. 
*Indicates P < 0.05. Values represent mean ± standard deviation (n =4) 
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calculated to be 359.0 ± 90.1 µM and 981.2 ± 115.67 nM respectively. Ki values of 
gatifloxacin and quinidine were calculated by the method of Cheng and Prusoff 
134
 and were 
estimated to be 385.5 ± 88.6 µM and 1.23 ± 0.161 µM respectively. 
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Figure 11. Dose dependent inhibition of [14C] erythromycin (0.25 µCi/mL, 51.3 
mCi/mmol) uptake in MDCKII-MDR1 cell monolayers in presence of gatifloxacin. 
Values represent mean ± standard deviation (n= 4) 
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Figure 12. Dose dependent inhibition of [14C] erythromycin (0.25 µCi/mL, 51.3 
mCi/mmol) uptake in MDCKII-MDR1 cell monolayers in presence of quinidine. Values 
represent mean ± standard deviation (n= 4) 
 
Dose-dependent inhibition of [
14
C] erythromycin uptake in MDCK-MRP2 cells in the 
presence of MK571 and gatifloxacin:  
Concentration dependent uptake of [
14
C] erythromycin in MDCK-MRP2 cells was 
studied in the presence of varying concentrations of MK571 and gatifloxacin. IC50 values of 
gatifloxacin and MK571 from the dose-response curves (Figs. 13 and 14) were calculated to 
be 5232 ± 390.5 µM and 188.4 ± 28.23 µM respectively. Ki values of gatifloxacin and 
MK571 were calculated by the method of Cheng and Prusoff 
134
 and were estimated to be 
5365 ± 218.4 µM and 174.71 ± 18.17 µM respectively. 
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Figure 13. Dose dependent inhibition of [14C] erythromycin (0.25 µCi/mL, 51.3 
mCi/mmol) uptake in MDCK-MRP2 cell monolayers in presence of gatifloxacin. 
Values represent mean ± standard deviation (n= 4) 
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Polarized [
14
C] erythromycin transport across MDCKII-MDR1 cell monolayers in 
presence of quinidine and varying concentrations of gatifloxacin: 
Bidirectional transcellular transport of [
14
C] erythromycin across MDCKII-MDR1 in 
presence of gatifloxacin (0.25, 0.5, 1 and 2.5 mM) was performed. [
14
C] Erythromycin 
transport alone was considered as the negative control and [
14
C] erythromycin in the presence 
of 75 μM quinidine served as the positive inhibitor for MDR1. A significant polarization in 
the transport of [
14
C] erythromycin across MDCKII-MDR1 cell monolayer was evident. 
Apparent permeability (Papp) value of [
14
C] erythromycin transport in the B–A direction was 
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Figure 14. Dose dependent inhibition of [14C] erythromycin (0.25 µCi/mL, 51.3 
mCi/mmol) uptake  in MDCK-MRP2 cell monolayers in presence of MK-571. Values 
represent mean ± standard deviation (n= 4) 
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more than fivefold higher than the AP–BL direction (Figure 15). Transport of [14C] 
erythromycin from apical to basolateral side across MDCKII-MDR1 monolayers was 
significantly elevated in the presence of gatifloxacin (0.25, 0.5, 1 and 2.5 mM) (Figure 15). 
No significant difference in [
14
C] erythromycin permeability was observed in the presence of 
0.5 mM to 2.5 mM in AP-BL direction. The same concentrations of gatifloxacin also showed 
marked inhibition of the BL–AP transport of [14C] erythromycin across the cell monolayers. 
Efflux ratios calculated as the ratio of Papp in AP-BL direction to BL-AP direction of the 
substrate were found to progressively decrease and approach unity with increasing 
concentrations of gatifloxacin. 
 
Figure 15. Dose dependent effect of gatifloxacin (0.25, 0.5, 1 and 2.5 mM) on the 
apparent permeability of [14C] erythromycin (0.25 µCi/mL, 51.3 mCi/mmol) across 
MDCKII-MDR1 cell monolayers. (-ve) represents transport of [14C] erythromycin 
alone, (+ve) represents transport of [14C] erythromycin in presence of quinidine (75 
μM). Transcellular transport of [14C] erythromycin was measured in the AP–BL and 
BL–AP direction. Values represent mean ± standard deviation (n= 4) 
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Polarized [
14
C] erythromycin transport across MDCK-MRP2 cell monolayers in the 
presence of MK-571 and varying concentrations of gatifloxacin:  
Bidirectional transcellular transport of [
14
C] erythromycin across MDCK-MRP2 cells 
in presence of gatifloxacin (0.25, 0.5, 1 and 2.5 mM) was monitored. [
14
C] Erythromycin 
transport alone served as the negative control and [
14
C] erythromycin in the presence of 100 
μM MK-571 was considered as the positive inhibitor for MRP2. A significant difference in 
polarized transport of [
14
C] erythromycin across MDCK-MRP2 cell monolayer was noted. 
Papp value of [
14
C] erythromycin transport in the BL-AP direction was more than 7 fold larger 
than in the AP-BL direction (Figure 16). Transport of [
14
C] erythromycin from apical to 
basolateral side across MDCK-MRP2 monolayers was significantly elevated in the presence 
of gatifloxacin (0.25, 0.5, 1 and 2.5 mM) (Figure 16). Same concentrations of gatifloxacin 
also showed marked inhibition in BL-AP directional transport of [
14
C] erythromycin. Efflux 
ratios continuously became lower and approached unity with increasing concentrations of 
gatifloxacin. 
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Figure 16. Dose dependent effect of gatifloxacin (0.25, 0.5, 1 and 2.5 mM) on the 
apparent permeability of [14C] erythromycin (0.25 µCi/mL, 51.3 mCi/mmol) across 
MDCK-MRP2 cell monolayers. (-ve) represents transport of [14C] erythromycin alone, 
(+ve) represents transport of [14C] erythromycin in presence of MK-571 (100μM). 
Transcellular transport of [14C] erythromycin was measured in the AP–BL and BL–
AP direction. Values represent mean ± standard deviation (n= 4) 
 
Accumulation of Hoechst 33342  
Accumulation of Hoechst 33342 (a specific BCRP substrate) was determined in 
confluent MDCK-BCRP cells. ABCG2 specific inhibitor Ko-143 (10 µM) was added as a 
positive control for the inhibition studies. Hoechst 33342 uptake was not found to be 
significantly different in a concentration dependent manner in presence of gatifloxacin (0.5, 
1, 2.5, 5 and 10 mM) (Fig. 10).  In presence of Ko-143 (10 µM), the dye uptake was found to 
rise by 2.5 fold (Figure 17).   
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Figure 17. Accumulation of 5µM Hoechst 33342 in MDCK-BCRP cells alone (-ve) and 
in presence of gatifloxacin (0.5, 1, 2.5, 5 and 10 mM). Ko143 (10µM) was used as a (+ve) 
inhibitor of BCRP mediated efflux. * Indicates P < 0.05. Values represent mean ± 
standard deviation (n=6) 
 
ATP activity assay 
An ATP activity assay was performed in all the MDCK cell lines post thirty minute 
treatment with gatifloxacin (0.75, 1.25, 2.5 and 5 mM).  Ouabain, sodium azide and 2,4 
dinitrophenol at a concentration of 1mM were used as positive inhibitors of ATP activity. No 
significant difference was observed in the ATP activity of the treated cells when compared to 
the vehicle control. Significant difference was observed in the activity in the presence of all 
the three inhibitors compared to the control (Figure 18).  
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Figure 18. ATP activity assay in MDCKII-MDR1, MDCK-MRP2 and MDCK-BCRP 
cells lines post 30 min treatment with different concentrations of gatifloxacin. Ouabain, 
sodium azaide, and 2,4 dinitro phenol were used as positive inhibitors of ATP. 
*Indicates P < 0.05. **Indicates P < 0.05. **Indicates P < 0.01. Values represent mean ± 
standard deviation (n =8) 
 
Discussion 
Gatifloxacin is a highly effective broad spectrum antibiotic indicated in treatment or 
prophylaxis of ophthalmic infections. The drug suffers from severe systemic toxicity issues 
135-136
 even though it shows negligible ocular toxicity 
137-138
. Development of drug resistance 
in ocular therapy has required an increase in dose which in turn may lead to systemic 
toxicity. The aim of the present study was to delineate the role of efflux transporters (P-gp, 
MRP2 and BCRP) in the development of gatifloxacin resistance. MDCK cells transfected 
with individual efflux transporters were selected as in vitro models to study the drug 
resistance. 
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Cellular uptake of [
14
C] erythromycin across MDCKII-MDR1 cells was enhanced by 
almost 2-fold in the presence of quinidine (75 μM). Gatifloxacin (2.5 mM) also raised the 
uptake of [
14
C] erythromycin by 1.6-fold even though at a much higher concentration (Figure 
9). This concentration of gatifloxacin is still less than the concentration used in marketed 
ophthalmic solution ZYMAR
® 
(0.3% w/v or approx. 8.0 mM). This 2-fold increase in the 
rate of erythromycin uptake by the MDCKII-MDR1 cell line in the presence of quinidine, a 
known substrate and/or inhibitor 
139
, confirmed that MDCKII-MDR1 cells express P-gp. A 
significant rise in erythromycin uptake by higher concentrations of gatifloxacin also suggests 
that this fluoroquinolone is a substrate of P-gp. 
In a similar study, cellular uptake of [
14
C] erythromycin across MDCK-MRP2 cells 
was also higher by 1.8-fold in the presence of MK571 (100μM), a known inhibitor of MRPs 
140
. Gatifloxacin (2.5 mM) also elevated the uptake of [
14
C] erythromycin by 1.7-fold (Figure 
10). These results confirm that MDCK-MRP2 cells express MRP2 and gatifloxacin is a 
substrate of MRP2.  
Affinity pattern of [
14
C] erythromycin in the presence of both quinidine and 
gatifloxacin was determined by dose-dependent studies in MDCKII-MDR1 cells. 
Lineweaver-Burk transformation of quinidine suggests noncompetitive inhibition of 
erythromycin efflux by P-gp whereas gatifloxacin appears to cause competitive inhibition, 
suggesting that quinidine and gatifloxacin may or may not share a common site of binding on 
the transporter (data not shown).  A comparison of Ki values indicates that quinidine probably 
exhibits much higher affinity toward P-gp relative to gatifloxacin (Figures 11 and 12). 
Similarly affinity pattern of [
14
C] erythromycin in the presence of both MK-571 and 
gatifloxacin was determined by dose-dependent studies in MDCK-MRP2 cells. The 
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Lineweaver-Burk transformation in this case suggested noncompetitive inhibition for MK-
571 and revealed competitive inhibition for gatifloxacin. These results suggest that MK-571 
and gatifloxacin may or may not share a common binding site on MRP2 (data not shown). A 
comparison of Ki values indicates that MK-571 probably has a much higher affinity toward 
MRP relative to gatifloxacin (Figures 13 and 14). 
A classical indication of the involvement of efflux in transport kinetics is the 
difference in permeation rates of the substrates in the apical to basolateral and basolateral to 
apical directions 
141
. If a compound is a substrate for P-gp, the apical to basolateral transport 
(AP-BL) is considerably lower than the basolateral to apical transport (BL-AP). The ratio of 
this transepithelial transport (AP-BL) vs. (BL-AP) is represented as efflux ratio and this ratio 
approaches one when the transport of a substrate at both directions remains same.  
Transepithelial bidirectional transport of [
14
C] erythromycin across MDCKII-MDR1 cells 
reveals that the transport in the absorptive direction (AP to BL) was significantly lower than 
in the secretory direction (BL to AP) (Figure 15). This asymmetric permeation is due to the 
apically polarized P-gp efflux transporter, for which erythromycin is a very good substrate. 
In the presence of quinidine (75 μM), the apparent permeability (Papp) for secretory 
transport of erythromycin decreased significantly where as the absorptive transport increased 
significantly bringing the efflux ratio down to 1.3 as compared to 7.2 in the control (Figure 
15). A similar concentration dependent decrease in the rate of secretory transport as well as 
increase in the absorptive transport rate was observed in the presence of gatifloxacin in 
MDCKII-MDR1 cells (Figure 15).  
In a similar study performed in MDCK-MRP2 cell monolayers, the transepithelial 
permeability of [
14
C] erythromycin in the basolateral to apical and apical to basolateral 
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direction again generated an efflux ratio of 5.3. Further, the efflux ratio across MDCK-MRP2 
cells in the presence of MK-571 (100 μM) decreased significantly (efflux ratio=1). A similar 
trend in decrease of (BL-AP) transport as well as increase in the (AP-BL) transport rate was 
evident in the presence of increasing concentrations of gatifloxacin (Figure 16). These results 
further confirm our earlier observations that gatifloxacin is recognized by both P-gp and 
MRP2 as a substrate. 
Uptake of the fluorescent substrate was found to rise significantly in presence of Ko-
143 confirming the presence of BCRP in MDCK-BCRP cells. However, such uptake was 
ineffective in the presence of different concentrations of gatifloxacin suggesting that this 
fluoroquinolone is not a substrate of BCRP (Figure 17).  
One possible reason for the inhibition of efflux observed in the presence of 
gatifloxacin can be its action on ATP. Since these efflux transporters are ATP dependent 
proteins, any decrease in amount or activity of ATP can result in the potential decrease in the 
sensitivity of the substrate for the transporter. To test this hypothesis an ATP assay was 
performed in the presence of various gatifloxacin concentrations in all the MDCK cell lines 
used during this study. The ATP activity did not diminish in any of the cells treated with 
gatifloxacin where as a significant decrease in the ATP activity was observed in the presence 
of all the three ATP inhibitors. Hence this negates the possibility of an indirect inhibition of 
P-gp and MRP2 mediated efflux by gatifloxacin via ATP inhibition (Figure 18). 
In this study we attempted to delineate the possible role of major efflux proteins in 
the acquired drug resistance of gatifloxacin. Initial uptake studies suggested a possible 
interaction between gatifloxacin and efflux transporters (P-gp, MRP2). Concentration 
dependent affinity analysis further suggested that gatifloxacin may act as a substrate for both 
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P-gp and MRP2. This hypothesis was further supported by the concentration dependent 
reduction in efflux ratios in both MDCKII-MDR1 and MDCK-MRP2 cells.  
Earlier reports by Li et al. studied the interaction of gatifloxacin with P-gp but did not 
find any significant involvement of the transporter in the translocation of gatifloxacin
142
. The 
cell line used in that study was rat endothelial cell line (RBMEC) which expresses relatively 
lesser amounts of P-gp. For this reason transfected cell lines were used in this study so that 
the expression of the efflux transporters can be assured.  
In conclusion, this report indicates that efflux transporters may play an important role in the 
development of gatifloxacin resistance which in turn may limit drug concentration at the 
target site or may inhibit drug uptake by the microbes. Knowledge of drug interaction with 
these efflux transporters can aid in the development of strategies to better circumvent these 
efflux transporters.  
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CHAPTER 4 
 
TRANSFECTED MDCK CELL LINE WITH ENHANCED EXPRESSION OF CYP3A4 
AND P-GLYCOPROTEIN AS A MODEL TO STUDY THEIR INTERACTIONS IN 
DRUG DETOXIFICATION 
 
NOTE: THIS WORK HAS BEEN IN DONE IN CONJUNCTION WITH BALASUBRAMANYAM BUDDA AND SOME PART OF 
THE DATA PRESENTED IN THIS CHAPTER HAS BEEN REPRODUCED WITH PERMISSION FROM BALASUBRAMANYAM 
BUDDA’S DISSERTATION 
 
Rationale 
 
One of the most important steps in oral drug development is the identification of 
potential drug candidates which have high permeability across the intestinal membranes and 
are also resistant to or can bypass first-pass metabolism altogether. Currently, the use of 
empirical screens such as permeability across cultured intestinal cell monolayers and 
metabolic stability studies within isolated sub cellular liver fractions are performed to select 
the best candidates for further drug development 
143
. 
Over the years a wide variety of in vitro systems have been utilized as models to 
study drug transport across the intestine. Caco-2 cells (a human colon carcinoma cell line), 
has been the most widely accepted model and it has become the “work-horse” for industry 
and other scientists working in the field of oral absorption. Its phenotypic characteristics are 
similar to that of normal intestinal absorptive cells. However, these cells have long culture 
time requiring 21 days of growth and are also very susceptible to contamination. Also, the 
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endogenous expressions of efflux transporters and metabolizing enzymes within these cells 
are much lower as compared to levels observed in human physiology. Hence, Caco-2 is not 
best suited model for the assessments of drug-drug interactions on a consistent basis. Madin-
Darby Canine Kidney (MDCK) cells, a renal epithelial cell line has been studied widely as a 
potential model to study drug permeability. When plated onto Transwells®, these cells 
differentiate into columnar epithelium and form tight junctions within 4-6 days 
144
. However, 
MDCK cells being derived from dog kidney also lack certain biochemical properties of 
intestinal cells. The importance of this limitation depends on the application. As previously 
mentioned a good correlation has been shown with regard to permeability across MDCK and 
Caco-2 cell monolayers and with human in vivo bioavailability
125
. 
Cytochrome P450 (CYP) is the largest family of metabolizing enzymes out of which 
Cytochrome P450 3A4 (CYP3A4) is the major contributor to xenobiotic metabolism. In a 
report Watkins et al. suggested that about 50% and 70% of currently administered drugs are 
CYP3A4 substrates 
145
. CYP3A4 is highly expressed in the liver and Intestine and accounts 
for approximately 30% of all hepatic CYP and more than 70% of intestinal CYP. The level 
of CYP3A4 expression, like all other CYP, varies at various locations within the gastro 
intestinal tract.  
A multidrug resistance (MDR1) gene product, P-glycoprotein (P-gp), was first 
characterized in the 1970s. It was identified as an ATP dependent transporter responsible for 
emergence of resistance in tumors by effluxing chemotherapeutic agents out of the cancer 
cells. P-gp is present at high levels in adrenal gland and kidney, intermediate levels in liver, 
lung, small intestine, colon and  at low levels in prostate, spleen, heart, skin, skeletal muscle, 
stomach and ovary
146-147
.  P-gp is also expressed in brain
148-151
, choroid plexus
152
, and 
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placenta
153
. This efflux protein displays a broad range of substrate specificity such as 
cyclosporin-A, taxol, dexamethasone, lidocaine, erythromycin, ketoconazole, rifampicin, 
fluoroquinolones, protease inhibitors and many anti-cancer agents
154-161
.  
When multiple drug therapies are prescribed, drug–drug interactions (DDIs) become 
an important consideration for the physicians and the patients undergoing the treatment. It 
has been estimated that adverse drug reactions are one of the leading cause of deaths in US 
hospitals, exceeding deaths by pneumonia and diabetes
162
. Inhibition or induction of a 
metabolizing enzyme and efflux transporters by the respective interacting agents are the 
major causes of pharmacokinetic drug-drug interactions
163-164
. It has also been hypothesized 
that the metabolizing enzymes and efflux transporters may act synergistically in limiting the 
systemic bioavailability of therapeutic agents. This is primarily expected because most of the 
substrates for P-gp, are also substrates for CYP3A4. Due to similarity in substrate specificity 
these proteins appear to act synergistically
165
. This synergism during the first pass effect has 
been recognized as a major barrier to oral absorption of many clinically effective drugs
166-169
. 
Close chromosomal location of P-gp and CYP3A4 genes, their expression in mature 
enterocytes along with their similar substrate specificity further suggests that the function of 
these two groups of proteins may be complementary in nature and may form a coordinated 
barrier to drug absorption
170
. Studies by Bennet et al. have also pointed towards a functional 
correlation linking in-vivo activity of P-gp and CYP3A4 in the small intestine
171-172
.  
Another factor that point towards a possible interplay between P-gp and CYP3A4 in 
drug disposition is the close proximity in the cellular localization of P-gp and CYP3A4 (P-gp 
at apical brush border membranes of villous enterocytes 
173
 and CYP3A4 at the endoplasmic 
reticulum below it)
174-175
. Hence, bioavailability of those co-substrates will be restricted by 
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both P-gp mediated efflux and CYP3A4-mediated metabolism
169, 175-176
. Lan et al suggested 
that P-gp can contribute to the extent of metabolism by CYP3A4 by affecting its availability 
to the enzyme
177
. 
Though in vitro models such as Caco-2, MDCK have been extensively used to delineate 
drug-drug interactions mediated by P-gp and CYP3A4, limited or lack of constitutive 
expression of these has been recognized as intrinsic weakness of these models. A rapid and 
stable in vitro cell culture model, MDCK-MDR1, with enhanced expression of P-gp has been 
developed to study the absorption barrier, particularly the efflux barrier (P-gp) at small 
intestine
144
. But MDCK-MDR1 alone cannot simulate exact environment present in the small 
intestine as it expresses only P-gp. Since small intestine is shown to express significant 
amounts of CYP3A4 in addition to efflux transporters, MDCK-MDR1 can be considered as 
an incomplete model of small intestine.   
Therefore, in our current study, we developed and characterized a modified MDCK 
cell line over expressing both CYP3A4 and P-gp as an in vitro model for evaluating oral 
bioavailability. Further, we attempted to test the hypothesis that drug-drug interactions 
involving both Pgp and CYP3A4 may have synergistic effects. To substantiate this, the effect 
of morphine and naringin (as interacting agents) was tested on the transport of 6β 
hydroxycortisone, a well-known P-gp and CYP3A4 substrate 
178-181
. Better knowledge of 
such interplay between efflux proteins and metabolizing enzymes may appear to facilitate the 
measurement of individual contribution of efflux and metabolic barriers. 
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Materials and Methods 
Materials 
Methadone, morphine, naringin, cortisol and β-Hydroxycortisol were obtained from 
Sigma Chemical Company (St. Louis, MO). All culture media and fetal bovine serum were 
obtained from Invitrogen (Carlsbad, CA). Lopinavir was provided as a generous gift by 
Abbott Laboratories. Human intestinal microsomes were obtained from Xenotech LLC 
(Kansas City, MO). Fetal bovine serum (FBS) was purchased from Atlanta Biologicals 
(Lawrenceville, GA). Culture flasks (75cm
2
 growth area), polyester transwells (pore size of 
0.4µm and 12mm diameter) and 96-well plates (0.32cm
2
 growth area per well) were 
purchased from Corning Costar Corp. (Cambridge, MA). G418, Lipofectamine™ 2000 
transfection reagent, Trizol-LS reagent and other molecular biology reagents were purchased 
from Invitrogen (Carlsbad, CA). All other chemicals were products of commercial biological 
grade and were obtained from Sigma Chemicals (St. Louis, MO) and Fisher Scientific. 
 
Cell Culture 
All the unmodified cell lines (MDCK-WT, HepG2 and Caco-2) were obtained from 
American Type Culture Collection (Manassas, VA). MDCK-MDR1 cells were obtained as 
generous gift from Dr. Peter Borst, Netherland’s Cancer Institute. MDCK-WT and Caco-2 
cells as well as MDCK-MDR1 (passages 4-12) were cultured in Dulbecco's modified Eagle's 
medium (DMEM) with 4.5 g/L glucose, supplemented with 10% (v/v) fetal bovine serum, 
penicillin-streptomycin (100 Units/L and 100 μg/mL, respectively), and 1% (v/v) 
nonessential amino acids. Cells were maintained at 37°C in a humidified atmosphere of 5% 
CO2 in air and sub cultured once 80% confluent. Semi-confluent cell monolayers were sub 
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cultured every 4 days using 0.25% trypsin containing 0.537 mM EDTA. HepG2 cells were 
grown in Minimum Essential Medium (MEM) containing Earl’s salts and 10% (v/v) heat 
inactivated fetal bovine serum under the similar conditions. 
 
Plasmid Preparation and Cell Transfection 
Plasmid expression vectors were constructed using standard protocols. We obtained 
human CYP3A4 cDNA (NM_017460.3) insert as 10 µg transfection-ready plasmid 
(pCMV6-Neo- CYP3A4) from Origene Technologies. The custom synthesized plasmid 
already contained neomycin resistance gene for stable transfection. The reconstituted plasmid 
was transfected using Lipofectamine™ 2000 Transfection Reagent (Carlsbad, CA). 
CYP3A4-NEO was introduced into MDCK-WT and MDCK-MDR1 cells according to 
manufacturer instructions. Briefly, cells were plated 1 day before the transfection in T-75 
flasks or 35-mm tissue culture plates at an appropriate cell density. Once 70-80 % confluent, 
plasmid was transfected in complete growth medium without a selection agent. Seventy-two 
hrs post transfection, cells were sub cultured (1:10 ratio) and grown in the medium 
containing selection agent, neomycin at a concentration of 20 μg/mL. Cells were maintained 
in the selection medium for about 2-3 weeks with fresh medium added every 24 hrs. Once 
confluent, cells were sub cultured again and plated as per the required experiments. 
 
Cell cytotoxicity Assay 
MTT assay is a very sensitive cell viability assay and was performed as reported 
earlier
182-183. Reagents were prepared as per manufacturer’s protocol. Viability assay was 
carried out in 96-well plates. Transfections were performed in scaled down manner exactly 
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like in the T-75 flasks described earlier. Following the transfection, cells were washed once 
with warm PBS and then replaced with 100 μL of fresh warm PBS in each well. Cells were 
incubated in a humidified 5% CO2 atmosphere for a period of 48 h to evaluate the cytotoxic 
effects. The commercial assay used (CellTiter 96 Aqueous Non-radioactive Cell Proliferation 
Assay Kit) constitutes a colorimetric method for determining the number of proliferating 
cells in culture. Cell viability was measured as the rate of fluorescent metabolite production 
(color formation) over the course of the reaction which is proportional to number of viable 
cells present. Color determination was measured at 485 nm (reference at 590 nm) using a 96-
well microtiter plate reader (SpectraFluor Plus; Tecan, Maennedorf, Switzerland). 
 
RT-PCR Analysis 
Total RNA was isolated from cells using Trizol-LS® reagent according to 
manufacturer’s instructions. RNA was quantified by UV absorbance at 260 nm. Briefly, 1 µg 
of total RNA was mixed with 2 µl of oligo dT15 primer and denatured at 70 
o
C for 10 
minutes. After denaturation, it was reverse transcribed using 1 µl (10 units) per reaction 
mixture of MMLV Reverse Transcriptase (Promega, Madison, WI). PCR was carried out in 
20 μL volumes containing 20 ng of each tissue cDNA as a template and 0.5 μmol each 
primer using Taq polymerase (Promega). Primers used for the amplification are included in 
Table 5. PCR conditions are as follows. All samples were preheated at 94 °C for 2 min and 
then subjected to denaturing conditions at 94 °C for 10 s. After annealing at 60 °C for 45 s, 
genes were amplified at 72 °C for 1.5 min (35 cycles). 
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Table 5. RT-PCR primers for CYP3A4, Product length 540bp 
 Sequence (5'->3') Template Length Tm GC% 
Forward AATCACTGTTGGCGTGGGG 2155-2173 19 54.80 57.89 
Reverse GCATCGAGACAGTTGGGTGT 2735-2716 20 54.54 55.00 
 
Quantitative Real Time PCR 
Real-time PCR was conducted using an ABI 5700 GeneAmp Sequence Detection 
System (Perkin – Elmer, Applied Biosystems, Foster City, CA) capable of detecting 
fluorescence between 500 nm to 660 nm and Roche - LightCycler® 480 System. Primers 
were designed using OligoPerfect™ Designer (Invitrogen Corp. Carlsbad, CA). All the 
primers were designed such that the amplicons generated will be 100-150 bp long to increase 
the efficiency of simultaneous amplification of target and reference genes (Table 6). The 
PCR mixture has a final volume of 40 μL and contains the relevant template cDNA, 250 nM 
each of forward and reverse primers for gene of interest, 1X Mg free PCR buffer (Promega), 
3.75 mM MgCl2, 0.025 units Taq Polymerase (Promega), 200 μM dNTPs, 1X ROX reference 
dye and 1X SYBR Green (Invitrogen). The specificity of the target amplicon was tested by 
melting curve analysis
184-185
. Quantitation was carried out using comparative Ct method. 
Samples for real-time PCR were prepared in triplicate. Quantitative values were 
obtained above the threshold PCR cycle number (Ct) at which the increase in signal 
associated with an exponential growth for PCR products is detected. The relative mRNA 
levels in each sample were normalized according to the expression levels of GAPDH/β-actin. 
For these studies, initial experiments were carried to make sure that the target and 
GAPDH/β-actin genes were amplified with equal efficiencies. An induction ratio 
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(treated/untreated) was determined from the relative expression levels of the target gene 
using equation 8. 
2
-ΔCt
 (ΔCt = Cttarget gene– CtGAPDH)
38……………………………………………….Eq 8. 
 
Table 6. Real Time PCR primers 
 Sequence (5'->3') Template Length Tm GC% 
Forward GCACCATTAACTCCTCCTGAGCT 1890-1912 23 56.27 52.17 
Reverse AGTTCTGACAAAGGCCCCACG 2187-2167 21 56.96 57.14 
 
Immunoblotting 
Confluent cells grown on T-75 flask (75 cm
2
 growth area) were washed twice with 
PBS and harvested with a cell scraper in 5 mL of PBS. Cell suspension was centrifuged at 
1500 rpm for 10 minutes and the pellet was re-suspended in freshly prepared lysis buffer 
(PBS containing 0.1% NP40 and protease inhibitor cocktail) for 15 minutes on ice. The cells 
were first ultrasonicated for 30 s and then centrifuged at 12000 rpm for 10 minutes at 4 
o
C. 
Total protein lysate was collected and stored at -80 
o
C, until used. Protein content was 
determined using Bradford method (Bio-Rad Protein Estimation Kit, Hercules, CA). The 
proteins (20 μg/lane) were then separated on ready-made Novex® 8-16% Tris-bis Gels 
(Invitrogen, Carlsband, CA) for 2 hrs at 120 V. Proteins were then transferred onto PVDF 
membranes for 2.5 hrs at 30V on ice using standard techniques. The blot was incubated in 
freshly prepared blocking buffer (3% w/v BSA and 5% non fat dry milk in phosphate 
buffered saline) for overnight at room temperature. It was then probed with antibody specific 
to CYP3A4 (Xenotech LLC, Kansas City, KS) at 37 
o
C for 2-3 hrs. Following five washes of 
10 minutes  in PBST (Phosphate buffered saline + 0.1% Tween 20), the blots were probed 
72 
 
with secondary antibody in PBST (1:2000 anti-mouse IgG-HRP). The blots were finally 
washed three times with PBST and then subjected to enhanced chemiluminescence using 
SuperSignal West Dura Kit (Pierce Biotechnology, Rockford, IL) and visualized by 
ChemiImager 8900 digital imaging system (Alpha Innotech, San Leandro, CA). The images 
of immunoreactive staining were measured and analyzed by AlphaEase software (Alpha 
Innotech). 
 
VIVID Assay 
CYP3A4 activity in MDCK-MDR1-CYP3A4 cells was assayed using the VIVID™ 
CYP3A4 Red Substrate (Invitrogen), which was prepared as a 20 mM stock solution in 
acetonitrile. Following transfection, the assay medium was removed and cells were washed 
once with warm PBS. Reagents were added according to the manufacturer’s protocol. 
Fluorescent readings were monitored kinetically at 37 °C over a period of 30 minutes using a 
96 well plate reader at an excitation wavelength of 530 nm and an emission wavelength of 
585 nm. Activity was measured as the rate of fluorescent metabolite production from the 
metabolism of a Vivid® CYP450 substrate over the course of the reaction. 
 
Cellular Transport Studies 
Transwell diffusion system was used for these studies. Prior to the experiment, cell 
monolayers grown on the Transwell™inserts were rinsed with Dulbecco’s Phosphate 
Buffered Saline (DPBS) and incubated at 37 
o
C. Drug solutions [Cortisol alone and in 
combination with Morphine (3μM) or Naringin (50μM)] in DPBS (pH 7.4) were placed in 
the donor chamber. The receiver chamber was filled with DPBS. Sampling from the receiver 
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chamber was done at predetermined time intervals and fresh DPBS solution was replaced to 
maintain sink conditions in receiver chamber. The samples were then analyzed by HPLC
186
. 
All experiments are performed at 37 
o
C. The effective permeability (cm/sec) was determined 
using the following Equation 9: 
  
     
       
………………………………………………………………………………Eq. 9. 
Where, P is the permeability in cm/sec, dC/dt is the slope of plot of concentration (nmoles) 
versus time (min), C is the concentration of drug (nmol/cm
3
), A is the surface area of the 
chamber (cm
2
), and V is the volume of each half-chamber (cm
3
). 
 
Data Analysis 
All experiments were conducted at least in triplicate and the results are expressed as 
mean ± SD. For comparing the treatment group (i.e., in the presence of inhibitors) with 
control, one-way analysis of variance followed by Dunnett's test was used to determine 
significance of data. For comparisons between two groups, the t test was used. The prior 
level of significance was set at p < 0.05. Statistical comparisons were performed student T 
test. 
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Results 
Expression of CYP3A4 mRNA in MDCK-MDR1 
RT-PCR analysis was carried out to confirm the expression of CYP3A4 mRNA after 
transfection. MDCK-MDR1 (host cells) and Caco-2 cells were used for the comparison 
purposes. This result suggests that transfected MDCK-MDR1 cells were able to express 
CYP3A4 mRNA 
(Figure 19) 
 
Figure 19. Expression of CYP3A4. 1. Molecular weight markers 2. MDCK-MDR1 cells 
3. Caco-2 cells 4. MDCK-MDR1 cells transfected with CYP3A4 
 
 
Immunoblotting 
Since purpose of developing this cell line is to have functionally active CYP3A4 
protein, we carried out immunoblot analysis to establish the presence of CYP3A4 protein 
using CYP3A4 specific monoclonal antibody (Xenotech LLC.). Immunoblot analysis 
showed that MDCK-WT and MDCK-MDR1 transfected with CYP3A4 expressed significant 
amounts of CYP3A4 protein (Lanes 3 and 5 in Figure 20) as compared to the host cell line. 
Human intestinal microsomes were used as positive controls (Lanes 9 in Figure 20). 
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Figure 20. Immunoblot showing 56.5 kD band for CYP3A4 protein: lane 1) molecular 
marker, lane 2) MDCK-WT, lane 3) MDCK-WT-CYP3A4, lane 4) MDCK-MDR1, lane 
5) MDCKMDR1- CYP3A4, lane 6) blank, lanes 7 through 9) human intestinal 
microsomes. Lanes 2-5 were loaded with 20 μg microsomal protein where as lanes 7 to 9 
were loaded with 10, 5 and 2.5 μg microsomal protein respectively. 
 
Cell Viability after Cell Transfection 
Since transfection reagents and foreign DNA can affect the cell survival, post 
transfection cell viability assays were conducted. Neither components of the transfection 
mixture alone nor transfection reagent and plasmid mixture produced any significant toxicity 
at the concentrations utilized (Figure 21). 
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Figure 21. Cell viability after the transfection procedure. Data was presented as mean ± 
SD. 1- Medium; 2- Plasmid only 3; Transfection reagent only and 4- Transfection 
reagent and Plasmid 
 
Comparative CYP3A4 mRNA Analysis in Transfected vs Non-Transfected Cells 
Quantitative Real Time PCR was used to compare the CYP3A4 mRNA in transfected 
cell lines versus the non-transfected cell lines. MDCK-WT cells served as the negative 
control, which was also observed to express some amount of CYP3A4 mRNA. Both MDCK-
WT and MDCK-MDR1 cells transfected with CYP3A4 plasmid appeared to express 
CYP3A4 mRNA more than 6-7 fold compared to non-transfected cells. Transfected cells 
were also compared against model cell lines such as Caco-2 (intestine) and HepG2 (liver) 
both of which showed just over 2-fold expression compared to MDCK-WT cells (Figure 22). 
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Figure 22. Comparative CYP3A4 mRNA levels in MDCK-WT, MDCK-MDR1, MDCK-
WTCYP3A4, MDCK-MDR1-CYP3A4, Caco-2 and HepG2 cells after CYP3A4-NEO 
transfection. All data were presented as mean ± SD. * indicates statistical significance at 
p<0.05 with n=6) 
 
VIVID™ Metabolism Assay for CYP3A4 Functional Activity 
Functional activity of CYP3A4 enzyme was then measured under the similar 
treatment conditions by VIVID CYP3A4 assay kit containing Red fluorescent substrate. 
Fluorescent metabolite formation in both MDCK-WT-CYP3A4 and MDCK-MDR1- 
CYP3A4 cell lines were almost 5-6 fold higher than host cells suggesting enhanced 
expression and activity of CYP3A4 (Figure 23). Non transfected cells were also found to 
show some basal metabolism.  
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Figure 23. Fluorescent metabolism assay for determining CYP3A4 functional activity in 
the transfected cells. 
 
Baculosomes which were used as the positive control for these studies showed similar 
activity to the two transfected cell lines. The ability of MDCK-MDR1- CYP3A4 cell line to 
express functionally active CYP3A4 protein was further evaluated by comparing it with 
recombinant CYP3A4 expressed in Baculosomes. Ketoconazole, a prototypic CYP3A4 
inhibitor, was used as a positive control for CYP3A4 inhibition (Figure 24).  
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Figure 24. Determination IC50 value for inhibition of CYP3A4-mediated metabolism of 
VIVID by ketoconazole in MDCK-MDR1-CYP3A4 cells in 96-well plates. Various 
concentrations of ketoconazole were incubated in the presence of 20 μM Vivid for 40 
minutes. Values are expressed as the % of control rates (absence of inhibitor). 
 
 
Transport of Cortisol Across MDCK-WT, MDCK-CYP3A4, MDCK-MDR1 and 
MDCK-MDR1-CYP3A4 
Transport of cortisol was carried out in all of the 4 cell lines and there was a 
significant decrease in active cortisol transport in the dual transfected verses the mono 
transfected verses the non-transfected cell lines (Figure 25a).  
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Figure 25. A) Transport of 200 μM cortisol in MDCK-WT and MDCK-MDR1 cells 
alone and transfected with CYP3A4. B) Time dependent formation of CYP3A4-
mediated metabolite of cortisol (6β-hydroxy cortisol). p<0.05, n = 6 ± S.D 
On similar lines a significantly higher amount of cortisol metabolite was formed in 
MDCK-WT transfected with CYP3A4 than MDCK-WT (Figure 25b). Maximum metabolite 
of cortisol (6β-hydroxy cortisol) was formed in MDCK-MDR1-CYP3A4 cells as compared 
to others (Figure 25b). 
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Transport of Cortisol in Presence of Morphine and Naringin across Transfected Cells 
Transport of cortisol was conducted in the presence of known interacting agents, 
morphine (drug of abuse) and naringin (herbal drug).  No significant difference in the cortisol 
permeability was observed in MDCK-WT cell line in presence of either of the interacting 
agents (Figure 26a & figure 27). A significant increase in cumulative transport of cortisol 
was observed in presence of both interacting agents in both the mono transfected cell lines 
(figure 26b and 26c). Naringin was found to be a stronger interacting agent when the 
transport was carried out across MDCK-MDR1-CYP3A4 cell line (Figure 26d). 
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Figure 26. Transport of 200 μM cortisol alone or in presence of Morphine (3μM) or 
Naringin (50μM) across (A) MDCK-WT, (B) MDCK-MDR1, (C) MDCK-CYP3A4, (D) 
MDCK-MDR1-CYP3A4 cell lines. p<0.05, n = 4 ± S.D. 
 
 
 
Figure 27. Permeabillity values for transport of 200 μM cortisol alone or in presence of 
Morphine (3μM) or Naringin (50μM) across MDCK-WT and MDCK-MDR1 cells alone 
and transfected with CYP3A4. p<0.05, n = 4 ± S.D. 
 
 
84 
 
Discussion 
Efflux transporters and metabolizing enzymes have both been known to play an 
essential role in the disposition of drugs in various organs of the body 
187-188
. Especially in 
the gastrointestinal system they play a key role in reducing the bioavailability of orally 
administered substrates. It has been proposed that both P-gp and CYP3A4 act in synergism to 
reduce the bioavailability of their common substrates. During in vitro screening of substrates, 
contribution of both P-gp and CYP3A4 towards drug disposition is studied separately. Due to 
the lack of existence of an in vitro system to study synergistic activity of these proteins, there 
overall contribution may get under estimated. Similarly, it is essential to screen potential 
drug interactions occurring upon co-administration of common substrates in a system which 
can accommodate this synergism so that more accurate estimates can be made 
189
. To 
develop such a system, MDCK cells were transfected with MDR1 and CYP3A4 genes so as 
to over-express both these proteins. Thus, both the proteins can be studied for their synergism 
in an isolated system, as MDCK cells do not express a significant amount of other efflux 
proteins.   
MDCK cells already transfected with MDR-1 gene were then transfected with 
CYP3A4 containing plasmid. Figures 20-22 clearly indicates transfection resulted in higher 
expression of CYP3A4 at both mRNA and protein levels. To confirm whether these protein 
expression levels also translated into increased activity of the protein, VIVID CYP activity 
assay was performed. This proprietary fluorescent substrate based assay from Invitrogen has 
been extensively used to measure the activity of CYP3A4 in in vitro systems. The assay 
results further confirmed that the protein being expressed in the transfected cell line was 
active (Figure 23).  
85 
 
Inhibitory assays are also often performed to confirm the presence of an active 
protein in an in vitro system. Inhibitory potency of ketoconazole in well-established in vitro 
assay employing recombinant CYP3A4 expressed in Baculosomes. The inhibitory activity of 
ketoconazole in this system was already reported with an IC50 value of 0.04 μM 190. 
Apparent IC50 values obtained for ketoconazole in our cell line assay was 0.21 μM (Figure 
24). One possible explanation for this lower inhibitory effect of ketoconazole observed in the 
cell based assays is the complex membrane structure of the cell line. The reduced cell 
membrane permeability and transport may result in lower intracellular concentrations of the 
inhibitor compared with Baculosomes hence resulting in elevated IC50. These results clearly 
showed the importance of this model cell line expressing simultaneously efflux proteins and 
metabolizing enzymes in assessing the contribution of each category of proteins.  
Similar to what was observed in Figure 23, a significantly higher amount of cortisol 
metabolite was formed in MDCK-WT transfected with CYP3A4 than MDCK-WT (Figure 
25b). However, metabolite formation in MDCK-WT which does not express CYP3A4 was 
an unexpected result. A quick review of the literature suggested that CYP3A5, a close 
homolog of CYP3A4 also metabolizes cortisol to 6β-hydroxy cortisol 191. In addition, it was 
already reported that kidney expresses CYP3A5 in significant amounts but not CYP3A4 
192
. 
Since MDCK was derived from kidney, it is no surprise that it exhibited the basal 
metabolism of CYP3A5. Therefore, we conclude that the increased metabolite formation in 
MDCK-WT-CYP3A4 cells is due to combined metabolism of transfected CYP3A4 as well as 
endogenous CYP3A5. 
Even more surprising was the increased metabolite formation in MDCK-MDR1. 
These studies also indicated that MDCK-MDR1 not only expresses CYP3A5 natively but the 
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efflux also synergizes the activity of the natively expressed metabolizing enzyme (Figure 
25b). MDCK-MDR1 which itself was derived from MDCK-WT is expected to express the 
same endogenous levels of CYP3A5 as MDCK-WT. In the case of common substrates for 
both CYP3A4/5 and P-gp, the latter effluxes the substrates out of the cell and in doing so it 
keeps the concentrations of substrates exposed to CYP3A4/5 metabolism well below the 
saturation leading to enhanced metabolism. Maximum metabolite of cortisol (6β-hydroxy 
cortisol) was formed in MDCK-MDR1-CYP3A4 cells as compared to others (Figure 25b). 
This increased cortisol metabolite formation was demonstrated in the MDCK-MDR1-
CYP3A4 cells due to the combined metabolic activity of CYP3A5, CYP3A4 and MDR1. 
Due to this very high metabolism and efflux observed in MDCK-MDR1-CYP3A4 no 
measurable amount of active drug was observed in the first hour of transport (Figure 25a).  
The main aim behind developing these transfected cell lines was to generate a model 
for studying drug-drug interactions. To validate this model, transport of cortisol was carried 
out along with known interacting agents, morphine (drug of abuse) and naringin (herbal 
drug).  The two interacting agents did not give any significant difference in the permeability 
when the transport was carried out in MDCK-WT cell line. Even though both MDCK-MDR1 
and MDCK-CYP3A4 cell lines did show increase in cumulative transport of cortisol in 
presence of either of the interacting agents, neither of these cells were able to differentiate 
much between the interacting capabilities of the two interacting agents. There was more 
significant difference in the transport levels achieved in the absence and presence of the 
interacting agents when the transport of cortisol was carried out in the dual transfected cell 
line. Further, better differentiation could be made between the intractability of the two agents 
in this cell line (Figure 26a-d and 27). Hence this cell line may be able to better predict which 
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agent may result in more physiologically relevant interaction than the other. Hence this cell 
line may prove to be a better model to study drug-drug interaction as it would incorporate the 
synergy between efflux and metabolism.  
 
Conclusion 
We developed a new cell line expressing both P-gp and CYP3A4 simultaneously. 
CYP3A4 cDNA was transfected into MDCK-WT and MDCK-MDR1 cells. Both gene 
expression and functional activity studies proved that MDCK cells were a good model and 
could express the CYP3A4 protein after transfection. This result also corroborates the 
previous report that MDCK was a better model for CYP3A4 transfection than some other cell 
lines 
193
. For the very first time, it was also shown that MDCK cells constitutively express 
CYP3A5 owing to their kidney source. We also showed that the wild type and mono-
transfected cell line can give over estimations of permeability and also they are not the best 
model to differentiate between different interacting agents. The dual transfected cell line due 
to higher interplay between efflux and metabolism gives better estimates of drug transport 
and also is a good cell line for studying drug-drug interactions. 
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CHAPTER 5 
 
DEVELOPMENT OF TRANSFECTED MDCK CELL LINE WITH ENHANCED 
EXPRESSION OF CYP3A4 AND MULTIDRUG RESISTANCE PROTEIN-2 (MRP-2) AS 
A MODEL TO STUDY THEIR INTERACTIONS IN DRUG DETOXIFICATION 
 
 
Rationale 
In vitro systems have been have played a very significant role as models to study drug 
transport across the intestine and over the years a wide variety of cell culture models have 
been in the developed. Out of these caco-2 cells has been the “work-horse” for industry and it 
has become the most widely accepted model to study oral absorption. As mentioned in 
previous chapters, its phonotypic characteristics are similar to that of normal intestinal 
absorptive cells. But the long culture time of 21 days and their high susceptibility to 
contaminations render them as a difficult model to work with. Also, their native expression 
levels of efflux transporters (such as MRP-2) and metabolizing enzymes such as (CYP3A4) 
are much lower as compared to the observed physiological levels. These cells are also very 
sensitive to transfection reagents and are extremely difficult to genetically engineer into cell-
types expressing elevated levels of desired proteins.  
Madin-Darby Canine Kidney (MDCK) cells, a renal epithelial cell line has been 
studied widely as a potential model to study drug permeability. These are rapidly dividing 
cells and when plated, fully characterize and form tight junctions within 4-6 days 
144
. Though 
these cells are not useful to study the cell biology of intestinal cells, a good correlation exists 
89 
 
between permeability across MDCK and Caco-2 cell monolayers and human in vivo 
bioavailability
125
. 
Cytochrome P450 (CYP) is the largest family of metabolizing enzymes out of which 
Cytochrome P450 3A4 (CYP3A4) is the major contributor to xenobiotic metabolism. In a 
report Watkins et al. suggested that about 50% and 70% of currently administered drugs are 
CYP3A4 substrates 
145
. CYP3A4 is highly expressed in the liver and intestine and accounts 
for approximately 30% of all hepatic CYP and more than 70% of intestinal CYP. The level 
of CYP3A4 expression, like all other CYP, varies at various locations within the 
gastrointestinal tract.  
A multidrug resistance (MDR) gene product, multidrug resistance protein 2 (MRP2), 
was discovered along with P-glycoprotein in multidrug resistant cell lines. It was identified 
as an ATP dependent transporter responsible for emergence of resistance in tumors by 
effluxing chemotherapeutic agents out of the cancer cells. Though its mechanism was similar 
to P-gp, unlike the former it was observed to have preference for glutathione S–conjugates194-
195
. Due to its relatively high ATP-dependent transport activity for organic anions, it is also 
called as canalicular multispecific organic anion transporter (cMOAT)
127
. This efflux protein 
displays a broad range of substrate specificity including substrates such as protease inhibitors 
and many anti-cancer agents
154-161
.  
When multiple drug therapies are prescribed, drug–drug interactions (DDIs) become 
an important consideration for the physicians and the patients undergoing the treatment. It 
has been estimated that adverse drug reactions are one of the leading cause of deaths in US 
hospitals, exceeding deaths by pneumonia and diabetes
162
. Inhibition or induction of a 
metabolizing enzyme and efflux transporters by the respective interacting agents are the 
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major causes of pharmacokinetic drug-drug interactions
163-164
. It has also been hypothesized 
that the metabolizing enzymes and efflux transporters may act synergistically in limiting the 
systemic bioavailability of therapeutic agents. This is primarily expected because efflux 
transporters such as P-gp, MRP2 share common substrates with CYP3A4. Due to similarity 
in substrate specificity these proteins appear to act synergistically
165
. This synergism during 
the first pass effect has been recognized as a major barrier to oral absorption of many 
clinically effective drugs
166-169
. Close chromosomal location of MRP2 and CYP3A4 genes, 
their expression in mature enterocytes along with their similar substrate specificity further 
suggests that the function of these two groups of proteins may be complementary in nature 
and may form a coordinated barrier to drug absorption
170
. Studies by Bennet et al. have also 
pointed towards a functional correlation linking in-vivo activity of P-gp and CYP3A4 in the 
small intestine and also in Caco-2 cells transfected with CYP3A4
171-172
.  
Another factor that point towards a possible interplay between MRP-2 and CYP3A4 
in drug disposition is the close proximity in the cellular localization of these two proteins. 
Lan et al have suggested that efflux transporters can contribute to the extent of metabolism 
by CYP3A4 by affecting its availability to the enzyme
177
. 
Though in vitro models such as Caco-2, MDCK have been extensively used to 
delineate drug-drug interactions mediated by MRP2 and CYP3A4, limited or lack of 
constitutive expression of these has been recognized as intrinsic weakness of these models. 
Often inducing agents are used to bring the expression levels of these proteins upto 
physiologically relevant levels, but the levels obtained are often not consistent. A rapid and 
stable in vitro cell culture model, MDCK-MRP2, with enhanced expression of MRP2 has 
been developed to study the absorption barrier, particularly the efflux barrier (MRP2) at 
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small intestine
127
. But MDCK-MRP2 alone cannot simulate exact environment present in the 
small intestine as it expresses only MRP2. Since small intestine is shown to express 
significant amounts of CYP3A4 in addition to efflux transporters, MDCK-MRP2 can be 
considered as an incomplete model of small intestine.   
Therefore, in our current study, we developed and characterized a modified MDCK cell line 
over expressing both CYP3A4 and MRP2 as an in vitro model for evaluating oral 
bioavailability.  
 
Materials and Methods 
Doxorubicin hydrochloride was obtained from Sigma Chemical Company (St. Louis, 
MO). All culture media and fetal bovine serum were obtained from Invitrogen (Carlsbad, 
CA). Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Lawrenceville, 
GA). Culture flasks (75cm
2
 growth area), polyester transwells (pore size of 0.4µm and 12mm 
diameter) and 96-well plates (0.32cm
2
 growth area per well) were purchased from Corning 
Costar Corp. (Cambridge, MA). G418, Lipofectamine™ 2000 transfection reagent, Trizol-LS 
reagent and other molecular biology reagents were purchased from Invitrogen (Carlsbad, 
CA). All other chemicals were products of commercial biological grade and were obtained 
from Sigma Chemicals (St. Louis, MO) and Fisher Scientific. 
 
Cell Culture 
All the unmodified cell lines (MDCK-WT, Caco-2) were obtained from American 
Type Culture Collection (Manassas, VA). MDCK-MRP2 cells were obtained as generous gift 
from Dr. Peter Borst, Netherland’s Cancer Institute. MDCK-WT and Caco-2 cells as well as 
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MDCK-MRP2 (passages 4-12) were cultured in Dulbecco's modified Eagle's medium 
(DMEM) with 4.5 g/L glucose, supplemented with 10% (v/v) fetal bovine serum, penicillin-
streptomycin (100 Units/L and 100 μg/mL, respectively), and 1% (v/v) nonessential amino 
acids. Cells were maintained at 37°C in a humidified atmosphere of 5% CO2 in air and 
subcultured once 80% confluent. Semi-confluent cell monolayers were subcultured every 4 
days using 0.25% trypsin containing 0.537 mM EDTA. HepG2 cells were grown in 
Minimum Essential Medium (MEM) containing Earl’s salts and 10% (v/v) heat inactivated 
fetal bovine serum under the similar conditions. 
 
Plasmid Preparation and Cell Transfection 
Plasmid expression vectors were constructed using standard protocols. We obtained 
human CYP3A4 cDNA (NM_017460.3) insert as 10 µg transfection-ready plasmid (
 pCMV6-XL4- CYP3A4) from Origene Technologies. The gene from the plasmid was 
then sub cloned into a vector containing puromycin resistance gene (pCMV-Puro) for 
mammalian selection necessary for stable transfection. The reconstituted plasmid was 
transfected using Lipofectamine™ 2000 Transfection Reagent (Carlsbad, CA). CYP3A4-
Puro was introduced into MDCK-WT and MDCK-MRP2 cells according to manufacturer 
instructions. Briefly, cells were plated 1 day before the transfection in T-75 flasks or 35-mm 
tissue culture plates at an appropriate cell density. Once 70-80 % confluent, plasmid was 
transfected in complete growth medium without a selection agent. Seventy-two hrs post 
transfection, cells were sub cultured (1:10 ratio) and grown in the medium containing 
selection agent, G418 at a concentration of 400 μg/mL. Cells were maintained in the 
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selection medium for about 2-3 weeks with fresh medium added every 24 hrs. Once 
confluent, cells were sub cultured again and plated as per the required experiments. 
 
Cell Cytotoxicity Assay 
MTT assay is a very sensitive cell viability assay and was performed as reported 
earlier
182-183. Reagents were prepared as per manufacturer’s protocol. Viability assay was 
carried out in 96-well plates. Transfections were performed in scaled down manner exactly 
like in the T-75 flasks described earlier. Following the transfection, cells were washed once 
with warm PBS and then replaced with 100 μL of fresh warm PBS in each well. Cells were 
incubated in a humidified 5% CO2 atmosphere for a period of 48 h to evaluate the cytotoxic 
effects. The commercial assay used (CellTiter 96 AQueous Non-radioactive Cell 
Proliferation Assay Kit) constitutes a colorimetric method for determining the number of 
proliferating cells in culture. Cell viability was measured as the rate of fluorescent metabolite 
production (color formation) over the course of the reaction which is proportional to number 
of viable cells present. Color determination was measured at 485nm (reference at 590nm) 
using a 96-well microtiter plate reader (SpectraFluor Plus; Tecan, Maennedorf, Switzerland). 
For optimization of selection of selection media concentration, the non-transfected 
cells were grown in 96 well plates and treated post confluence for 72 hrs with different 
concentrations of selection media. Same kit using similar protocol was used to determine the 
percentage viable cells. Cells exposed to media not containing puromycin were used as 
control. 
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RT-PCR Analysis 
Total RNA was isolated from cells using Trizol-LS® reagent according to 
manufacturer’s instructions. RNA was quantified by UV absorbance at 260 nm. Briefly, 1 µg 
of total RNA was mixed with 2 µL of oligo dT15 primer and denatured at 70 
o
C for 10 
minutes. After denaturation, it was reverse transcribed using 1 µL (10 units) per reaction 
mixture of MMLV Reverse Transcriptase (Promega, Madison, WI). PCR was carried out in 
20-μL volumes containing 20 ng of each tissue cDNA as a template and 0.5 μmol each 
primer using Taq polymerase (Promega). Primers used for the amplification are included in 
Table 1. PCR conditions are as follows. All samples were preheated at 94 °C for 2 min and 
then subjected to denaturing conditions at 94 °C for 10 s. After annealing at 60° C for 45 s, 
genes were amplified at 72 ° C for 1.5 min (35 cycles). 
 
Table 7. RT-PCR primers for CYP3A4 
 Sequence (5'->3') Template Length Tm GC% 
Forward AATCACTGTTGGCGTGGGG 2155-2173 19 54.80 57.89 
Reverse GCATCGAGACAGTTGGGTGT 2735-2716 20 54.54 55.00 
 
Quantitative Real Time PCR 
Real-time PCR was conducted using an ABI 5700 GeneAmp Sequence Detection 
System (Perkin – Elmer, Applied Biosystems, Foster City, CA) capable of detecting 
fluorescence between 500 nm to 660 nm and Roche - LightCycler® 480 System. Primers 
were designed using OligoPerfect™ Designer (Invitrogen Corp. Carlsbad, CA). All the 
primers were designed such that the amplicons generated will be 100-150 bp long to increase 
the efficiency of simultaneous amplification of target and reference genes (Table 8). The 
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PCR mixture has a final volume of 40 μL and contains the relevant template cDNA, 250 nM 
each of forward and reverse primers for gene of interest, 1X Mg free PCR buffer (Promega), 
3.75 mM MgCl2, 0.025U Taq Polymerase (Promega), 200 μM dNTPs, 1X ROX reference 
dye and 1X SYBR Green (Invitrogen). The specificity of the target amplicon was tested by 
melting curve analysis 
184-185
. Quantitation was carried out using comparative Ct method. 
Samples for real-time PCR were prepared in triplicate. Quantitative values were 
obtained above the threshold PCR cycle number (Ct) at which the increase in signal 
associated with an exponential growth for PCR products is detected. The relative mRNA 
levels in each sample were normalized according to the expression levels of GAPDH/β-actin. 
For these studies, initial experiments were carried to make sure that the target and 
GAPDH/β-actin genes were amplified with equal efficiencies. An induction ratio 
(treated/untreated) was determined from the relative expression levels of the target gene 
using equation 10: 
2
-ΔCt
 (ΔCt = Cttarget gene– CtGAPDH)
38………………………………………………………Eq10 
 
Table 8. Real time PCR primers for CYP3A4 
 Sequence (5'->3') Template Length Tm GC% 
Forward GCACCATTAACTCCTCCTGAGCT 1890-1912 23 56.27 52.17 
Reverse AGTTCTGACAAAGGCCCCACG 2187-2167 21 56.96 57.14 
 
Immunoblotting 
Confluent cells grown on T-75 flask (75 cm
2
 growth area) were washed twice with 
PBS and harvested with a cell scraper in 5 mL of PBS. Cell suspension was centrifuged at 
1500 rpm for 10 minutes and the pellet was re-suspended in freshly prepared lysis buffer 
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(PBS containing 0.1% NP40 and protease inhibitor cocktail) for 15 minutes on ice. The cells 
were first ultrasonicated for 30 s and then centrifuged at 12000 rpm for 10 minutes at 4 
o
C. 
Total protein lysate was collected and stored at -80 
o
C, until used. Protein content was 
determined using Bradford method (Bio-Rad Protein Estimation Kit, Hercules, CA). The 
proteins (20 μg/lane) were then separated on ready-made Novex® 8-16% Tris-bis Gels 
(Invitrogen, Carlsband, CA) for 2 hrs at 120 V. Proteins were then transferred onto PVDF 
membranes for 2.5 hrs at 30V on ice using standard techniques. The blot was incubated in 
freshly prepared blocking buffer (3% w/v BSA and 5% non fat dry milk in phosphate 
buffered saline) for overnight at room temperature. It was then probed with antibody specific 
to CYP3A4 (Xenotech LLC, Kansas City, KS) at 37 
o
C for 2-3 hrs. Following five 10-minute 
washes in PBST (Phosphate buffered saline + 0.1% Tween 20), the blots were probed with 
secondary antibody in PBST (1:2000 anti-mouse IgG-HRP). The blots were finally washed 
three times with PBST and then subjected to enhanced chemiluminescence using 
SuperSignal West Dura Kit (Pierce Biotechnology, Rockford, IL) and visualized by 
ChemiImager 8900 digital imaging system (Alpha Innotech, San Leandro, CA). The images 
of immunoreactive staining were measured and analyzed by AlphaEase software (Alpha 
Innotech). 
 
VIVID Assay 
CYP3A4 activity in MDCK-MRP2-CYP3A4 cells was assayed using the VIVID™ 
CYP3A4 Red Substrate (Invitrogen), which was prepared as a 20mM stock solution in 
acetonitrile. Following transfection, the assay medium was removed and cells were washed 
once with warm PBS. Reagents were added according to the manufacturer’s protocol. 
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Fluorescent readings were monitored kinetically at 37°C over a period of 30 minutes using a 
96 well plate reader at an excitation wavelength of 530 nm and an emission wavelength of 
585 nm. Activity was measured as the rate of fluorescent metabolite production from the 
metabolism of a Vivid® CYP450 substrate over the course of the reaction. 
 
Cellular Efflux Studies 
Efflux studies were performed in 12-well tissue culture-treated plates with confluent 
cells (MDCK-wt, MDCK-MRP2 and MDCK-MRP2-CYP3A4), usually 5 days post seeding. 
The medium was aspirated from wells and cells were washed (3 ×10 min) with 2 mL of 
Dulbecco’s phosphate-buffered saline (DPBS) containing 130 mM NaCl, 2.5 mM KCl, 7.5 
mM Na2HPO4, 1.5 mM KH2PO4, 1 mM CaCl2, 0.5 mM MgSO4, 5 mM glucose, and 20 mM 
HEPES at pH 7.4. Then 1 mL of drug solutions (0.25 μCi/mL of [14C] Erythromycin) was 
added to the cells and incubated at 37
0
C for 30 min. Then, solutions were removed, cells 
were washed with DPBS and then fresh DPBS was added and cells were incubated for 
further 30 min. Aliquots (500µL) of the incubated DPBS were then added to scintillation 
vials containing 3 mL of scintillation cocktail (Fisher Scientific, Fair Lawn, NJ) and 
radioactivity was measured with a scintillation counter (Model LS-6500; BeckmanCounter, 
Fullerton, CA), which can measure [
14
C] compounds with an efficiency of 95%. Efflux in 
each well was normalized to protein content, estimated by the Bio-Rad protein estimation kit 
using bovine serum albumin as the standard.  
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Cellular Transport Studies 
Transwell diffusion system was used for these studies. Prior to the experiment, cell 
monolayers grown on the Transwell™inserts were rinsed with Dulbecco’s Phosphate 
Buffered Saline (DPBS) and incubated at 37 
o
C. Drug solution (Doxorubicin) in DPBS was 
placed in the donor chamber. The receiver chamber was filled with DPBS. Sampling from 
the receiver chamber was done at predetermined time intervals and fresh DPBS solution was 
replaced to maintain sink conditions in receiver chamber. The samples were then analyzed by 
HPLC 
196
. All experiments are performed at 37 
o
C. The effective permeability (cm/sec) was 
determined using the following Equation 10: 
  
     
       
………………………………………………………………………………Eq 11. 
Where, P is the permeability in cm/sec, dC/dt is the slope of plot of concentration (nmoles) 
versus time (min), C is the concentration of drug (nmoles/ cm
3
), A is the surface area of the 
chamber (cm
2
), and V is the volume of each half-chamber (cm
3
). 
 
Data Analysis 
All experiments were conducted at least in triplicate and the results are expressed as 
mean ± SD. For comparing the treatment group (i.e., in the presence of inhibitors) with 
control, one-way analysis of variance followed by Dunnett's test was used to determine 
significance of data. For comparisons between two groups, the t test was used. The prior 
level of significance was set at p < 0.05. Statistical comparisons were performed student T-
test. 
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Results 
Expression of CYP3A4 mRNA in MDCK-MRP2 
RT-PCR analysis was carried out to confirm the expression of CYP3A4 mRNA after 
transfection. MDCK-MRP2 (host cells), MDCK-WT, MDCK-WT-CYP3A4 and Caco-2 
cells were used for the comparison purposes. Results suggested that transfected MDCK-
MRP2 cells were able to express CYP3A4 mRNA (Figure 28) 
 
Figure 28. Expression of CYP3A4 mRNA  1) Molecular weight ladder 2) MMrC 3) 
MDCK-WT 4) MDCK-WT-CYP3A4  5)MDCK-MRP2 6) Caco-2 
 
Immunoblotting 
Since purpose of developing this cell line is to have functionally active CYP3A4 
protein, we carried out immunoblot analysis to establish the presence of CYP3A4 protein 
using CYP3A4 specific monoclonal antibody (Xenotech LLC.). Immunoblot analysis 
showed that MDCK-MRP2 transfected with CYP3A4 expressed significant amounts of 
CYP3A4 protein (Lane 3 in Figure 29 ) as compared to the host cell line.  
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Figure 29. Western Blot for CYP3A4 protein 1) Molecular marker lane 2) MDCK-
MRP2 3) MMrC 
 
Optimization  of Puromycin Concentration 
To optimize the concentration of puromycin required for the selection of stably 
transfected cell lines, cell viability of MDCK-MRP2 cells after growing them for 5 days in 
medium containing different concentrations of Puromycin sulfate. 8 µg/mL concentration of 
puromycin in selection media was sufficient to kill all non-transfected cells (Figure 30). Cells 
exposed to media containing no puromycin was used as negative control and wells 
containing only media and no cells were used as positive control. 
 
Figure 30. Cell viability of MDCK-MRP2 cells after growing them for 5 days in 
medium containing different concentrations of Puromycin sulfate 
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Cell Viability after Cell Transfection 
Since transfection reagents and foreign DNA can affect the cell survival, post 
transfection cell viability assays were conducted. Neither components of the transfection 
mixture alone nor transfection reagent and plasmid mixture produced any significant toxicity 
at the concentrations utilized (Figure 31). 
 
Figure 31. Cell viability after the transfection procedure. Cells exposed for 23 hrs to 1-
Medium; 2- Plasmid only 3; Transfection reagent only and 4- Transfection reagent and 
Plasmid. * represents P value < 0.05 
 
Comparative CYP3A4 mRNA Analysis in Transfected vs Non-Transfected Cells 
Quantitative Real Time PCR was used to compare the CYP3A4 mRNA in transfected 
cell lines versus the non-transfected cell lines. MDCK-WT cells were used as the control cell 
line which was observed to express some amount of CYP3A4 mRNA. MDCK-MRP2-
CYP3A4 cells appeared to express CYP3A4 mRNA more than 17 fold compared to non- 
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transfected cells. Transfected cells were also compared against model cell lines such as Caco-
2 (intestine) and HepG2 (liver) both of which showed just over 2-fold expression compared 
to MDCK-WT cells (Figure 32). 
 
Figure 32. Comparative CYP3A4 mRNA levels normalized to GAPDH mRNA in 
MDCK-MRP2, MDCK-MRP2-CYP3A4, HEPG2, Caco-2 cells. * represents P value < 
0.05, ** represents P value <0.01 
 
Efflux of [
14
C] Erythromycin in Transfected vs Non Transfected Cell Lines 
Efflux of [
14
C] erythromycin was studied in both the mono and dual transfected cell 
lines, MDCK-wt cells were used as control. MDCK-MRP2 cells showed around 3.5 times 
more efflux than wild type cells which is as expected. The efflux of erythromycin was found 
to be significantly higher in MDCK-MRP2-CYP3A4 as compared to both the MDCK-MRP2 
as well as the wild type cells (around 4.5 fold) (Figure 33). Non transfected cells also showed 
measurable amount of efflux. 
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Figure 33. Efflux of [
14
C] erythromycin from MDCK-WT, MDCK-MRP2 and MDCK-
MRP2-CYP3A4 cells. * represents significant difference from control with p value < 
0.05 
 
Vivid™ Metabolism Assay for CYP3A4 Functional Activity 
Functional activity of CYP3A4 enzyme was then measured under the similar 
treatment conditions by VIVID CYP3A4 assay kit containing Red fluorescent substrate. 
Fluorescent metabolite formation  MDCK-MRP2- CYP3A4 cell lines were almost 9-10 fold 
higher than host cells suggesting enhanced expression and activity of CYP3A4 (Figure 34). 
Surprisingly MDCK-MRP2 cells also showed 2 fold higher level of metabolism when 
compared to non-transfected wild type cells. Non transfected cells also did show some basal 
metabolism.  
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Figure 34. Fluorescent metabolism assay for determining CYP3A4 functional activity in 
MDCK-WT, MDCK-MRP2, MDCK-WT-CYP3A4, MMrC cells. * represents 
significant difference from control with p value < 0.05 
 
Transport of Doxorubicin across Mono and Dual Transfected Cell Lines 
Transport of doxorubicin was carried out across mono and dual transfected cell lines 
and there was a significant decrease in active cortisol transport in the dual transfected versus 
the mono transfected versus the non-transfected cell lines (Figure 35). 
 
* 
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Figure 35. Cumulative amount of Doxorubicin transported through cell monolayers of 
trasfected (MDCK-MRP2-CYP3A4) and non-transfected (MDCK-MRP2) cells. 
 
Discussion 
Efflux transporters and metabolizing enzymes have both been known to play an 
essential role in the disposition of drugs in various organs of the body
187-188
. Especially in the 
in gastrointestinal system they play a key role in reducing the bioavailability of orally 
administered substrates. It has been proposed that both MRP-2 and CYP3A4 act in synergism 
to reduce the bioavailability of their common substrates. During in vitro screening of 
substrates, contribution of both MRP-2 and CYP3A4 towards drug disposition is studied 
separately. Due to the lack of existence of an in vitro system to study synergistic activity of 
these proteins, there overall contribution may get under estimated. Similarly, it is essential to 
screen potential drug interactions occurring upon co-administration of common substrates in 
a system which can accommodate this synergism so that more accurate estimates can be 
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made
189
. To develop such a system, MDCK cells were transfected with MRP2 and CYP3A4 
genes so as to over-express both these proteins. Thus, both the proteins can be studied for 
their synergism in an isolated system, as MDCK cells do not express a significant amount of 
other efflux proteins.   
MDCK cells already transfected with MRP2 (cMOAT) gene were then transfected 
with CYP3A4 containing plasmid. An ideal model for studying the interplay between efflux 
and metabolism should not only express high amounts of both but also at consistent levels. 
Hence with the aim of developing a stable cell line plasmid containing puromycin resistance 
gene was used for transfection. To optimize for the concentration of selection media 
required, difference concentrations of puromycin were exposed to the host cells. The 
minimum concentration of puromycin that causes complete cell death would be ideal for 
stable selection, which was found to be 8 µg/mL (Figure 30). Also often it has been observed 
that transfection mixtures can cause significant toxicity to the cells hence resulting in very 
low transfection efficiencies. Hence the cytotoxicity of the individual components of 
transfection mixture alone and in combination were studied on the cells. None of the 
components showed any significant toxicities at the concentrations used.  
 Figures 28-29 and 32 clearly indicates transfection resulted in higher expression of 
CYP3A4 at both mRNA and protein levels. To confirm whether these protein expression 
levels also translated into increased activity of the protein, VIVID CYP activity assay was 
performed. This proprietary fluorescent substrate based assay from Invitrogen has been 
extensively used to measure the activity of CYP3A4 in in vitro systems. The assay results 
further confirmed that the protein being expressed in the transfected cell line was active 
(Figure 34). However, metabolite formation in MDCK-WT which does not express CYP3A4 
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was an unexpected result. it was already reported that kidney expresses CYP3A5 in 
significant amounts but not CYP3A4
192
. Since MDCK was derived from kidney, it is no 
surprise that it exhibits the basal metabolism of CYP3A5. Therefore, we conclude that the 
presence of metabolic activity MDCK-WT cells is due to metabolism by endogenous 
CYP3A5. Even more surprising was the increased metabolite formation in MDCK-MRP2. 
These studies also indicated that MDCK-MRP2 not only expresses CYP3A5 natively but the 
efflux also synergizes the activity of the natively expressed metabolizing enzyme (Figure 
34). MDCK-MRP2 which itself was derived from MDCK-WT is expected to express the 
same endogenous levels of CYP3A5 as MDCK-WT. In the case of common substrates for 
both CYP3A4/5 and MRP2, the latter effluxes the substrates out of the cell and in doing so it 
keeps the concentrations of substrates exposed to CYP3A4/5 metabolism well below the 
saturation leading to enhanced metabolism. 
Since this is a two component system, it is also necessary to make sure that both the 
components are active. Hence to make sure that MRP2 is being actively expressed. Efflux 
studies were carried out using erythromycin (a known MRP2 substrate). As expected, the 
efflux in both the cell lines expressing MRP2 was significantly higher than what was 
observed in the wild type cell line (Figure 33). What was interesting to observe was that the 
level of efflux in MDCK-MRP2-CYP3A4 was slightly (yet statistically significant) higher 
than what was observed in MDCK-MRP2. This suggests that the presence of the 
metabolizing enzyme also aids in the efflux activity of the transporter. 
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Conclusion 
A stably transfected cell line expressing both efflux transporter (MRP2) and 
metabolizing enzyme (CYP3A4) has been developed to study the interplay between these 
two proteins. It has been hypothesized that these two proteins act in synergism to aid in 
reduction of xenobiotic entry into systemic circulation. For the first time it has been shown 
that in case of CYP3A4, MRP2 combination, the efflux aids in metabolism by allowing the 
enzyme greater time to metabolize the drug without getting saturated. Also it was observed 
that presence of the metabolizing enzyme also aids in the efflux of the common substrates. 
Hence these results points towards bidirectional synergism between MRP2 and CYP3A4. 
These results clearly showed the importance of this model cell line expressing 
simultaneously efflux proteins and metabolizing enzymes in assessing the contribution of 
each category of proteins.  
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CHAPTER 6 
 
DEVELOPMENT OF AN INTEGRATED SIMULTANEOUS ABSORPTION AND 
METABOLISM IN-VITRO CELL CULTURE MODEL TO STUDY THE DRUG EFFLUX 
AND METABOLISM SIMULTANEOUSLY DURING FIRST PASS EFFECT 
 
Rationale 
In vitro and in silico systems have been extensively used as models to assess the 
potential of drug candidates to overcome the physical and metabolic barriers presented by the 
intestinal epithelia. The most frequently used cell culture model for screening of intestinal 
permeability are cell cultures, predominantly the Caco-2 cells, both as low-throughput and as 
automated high-throughput variants 
197
. Although widely used, it is not easy to perform 
experiments using Caco-2 cells as they are not passive membranes. The Caco-2 cells express 
many enzymes representing normal human small intestine 
198
. However, activity of the most 
important metabolizing enzyme in the human gut, CYP3A4, is low or absent in the parent 
Caco-2 clone. Therefore, the permeability value and subsequently the prediction of fraction 
absorbed for substrates to 3A4 is generally overestimated in this cell line 
198
.  
Other cell lines forming monolayers, such as the human colon goblet cell line HT-29, 
HT-29-18-C1 subclone, Caco-2 cell subclone TC7, the human epithelial crypt cell lineT84, 
the rat small intestinal cell line IEC-18, and the rat duodenal cell line 2/4/A1, have all been 
developed to serve mechanistic evaluation of drug permeability but all these cell lines have 
been less evaluated with respect to enzyme and transporter expression 
198
. 
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Madin Darby Canine kidney (MDCK) cells have replaced Caco-2 in many research  
organizations as rapid and stable in vitro cell culture model because when grown onto 
Transwells®, MDCK cells differentiate into columnar epithelium and form tight junctions in 
a shorter period of time than Caco-2 cells (4 days vs. 21days) 
199
. It is also well recognized 
that MDCK cells serve more of a passive membrane model than Caco-2 cells 
199
. However, 
lack of efflux transporter expression in wild-type MDCK cells has led to the development of 
another variant, MDCK-MDR1 to study the absorption barrier, particularly the efflux barrier. 
MDCK-MDR1 cells are MDCK cells transfected with MDR1 gene over-expressing P-
glycoprotein and they can be used for the experiments within 4-6 days. These cells are often 
employed as a model for P-gp mediated efflux studies. A good correlation between the 
permeation of passively absorbed drugs in Caco-2 cells and MDCK-MDR1 cells has been 
reported 
200
. 
The biological activity and eventual toxicity of drugs are often dependent on drug 
metabolism. As a part of drug development process, pharmaceutical companies are mandated 
by regulatory agencies to study the metabolism of a given drug candidate. Until now, most of 
these studies have been carried out in vivo using experimental animals, especially small 
vertebrates. Since xenobiotic biotransformation is predominantly carried out in the liver 
parenchymal cells, several in vitro models such as perfused liver, liver slices, homogenates, 
microsomal suspensions and liver cell lines
201-206
 have been developed. Microsomes continue 
to be the first-line screening model for high throughput assays. A disadvantage of 
microsomes or recombinant enzymes is that they do not represent the true physiological 
environment 
207
. The establishment of long-term cultures of primary hepatocytes has long 
been desired and many efforts have been undertaken to achieve this goal but significant 
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longevity has not yet been achieved
208
. Isolated hepatocytes are relevant and practical models 
in which the study of drug metabolism and transporter interactions only when isolated and 
handled appropriately
209-211
. Even though they contain a broad complement of metabolizing 
enzymes and transport proteins, organized in a physiologically relevant context and regulated 
via cellular processes that occur within the liver in vivo (e.g. nuclear hormone-mediated 
xenosensors). The major limitation in using hepatocyte cultures to study drug metabolism is 
the rapid loss of cytochrome P-450 and phase II catalyzing enzymes after isolation
206
. The 
liver based cell line HepG2 has been extensively used as a cell line for modeling liver 
activity but the expression levels of CYP3A4 in this cell line are relatively low. Therefore in 
this study we have developed HepG2 cell line stably transfected to express CYP3A4 
(HepG2-CYP3A4)   
MDCK-MDR1 alone cannot simulate exact conditions present in the small intestine 
as it expresses only P-glycoprotein. Since small intestine is shown to express significant 
amounts of CYP3A4 in addition to efflux transporters, MDCK-MDR1 is an incomplete 
model of small intestine. Therefore, we have developed a modified MDCK cell line 
expressing both MDR1 and CYP3A4 simultaneously (MDCK-EM). This is important 
because P-glycoprotein and CYP3A4 act in concert to limit the bioavailability of number of 
drugs
172, 212-214
. While P-gp/CYP3A4 combination is known to be responsible for limiting 
drug bioavailability, individual contribution of each protein has never been determined. 
Increased knowledge of such interplay between various efflux proteins and metabolizing 
enzymes may facilitate the prediction of possible interactions with more accuracy. 
Orally administered drug faces two kinds of barriers before entering systemic 
circulation; small intestine and liver. While MDCK-EM can simulate the small intestine, in 
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order to better predict in vivo bioavailability from in vitro data, there is a need for a system 
where both small intestine and liver are represented. Although different methods to evaluate 
pharmaceutical properties have been integrated previously, much less attention has been paid 
in integrating intestinal absorption and liver metabolism. Therefore, in this study we have 
tried to develop and validate an integrated simultaneous absorption and metabolism model 
consisting of MDCK-EM and HepG2-CYP3A4 together to study the drug efflux and 
metabolism simultaneously both in small intestine and liver. This in vitro Transwell® based 
cell culture system will be more helpful for the discovery group in an industry setting to fast 
screen the drugs used in oral drug delivery and a better model for screening drug interactions. 
 
Materials and Methods 
Materials  
Doxorubicin hydrochloride was obtained from Sigma Chemical Company (St. Louis, 
MO). All culture media and fetal bovine serum were obtained from Invitrogen (Carlsbad, 
CA). Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Lawrenceville, 
GA). Culture flasks (75cm
2
 growth area), polyester transwells (pore size of 0.4µm and 12mm 
diameter) and 96-well plates (0.32cm
2
 growth area per well) were purchased from Corning 
Costar Corp. (Cambridge, MA). G418, Lipofectamine™ 2000 transfection reagent, Trizol-LS 
reagent and other molecular biology reagents were purchased from Invitrogen (Carlsbad, 
CA). All other chemicals were products of commercial biological grade and were obtained 
from Sigma Chemicals (St. Louis, MO) and Fisher Scientific. 
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Cell Culture 
Lopinavir was a generous gift from Abbott Laboratories. All the unmodified cell lines 
(MDCK-WT, HEPG2) were obtained from American Type Culture Collection (Manassas, 
VA). MDCK-MDR1 cells were obtained as generous gift from Dr. Peter Borst, Netherland’s 
Cancer Institute. MDCK-MDR1-CYP3A4 cells were prepared in our lab. MDCK-WT, 
MDCK-MDR1 (passage 4-12) as well as MDCK-MDR1-CYP3A4 (passages 1-4) were 
cultured in Dulbecco's modified Eagle's medium (DMEM) with 4.5 g/L glucose, 
supplemented with 10% (v/v) fetal bovine serum, penicillin-streptomycin (100 Units/L and 
100 μg/mL, respectively), and 1% (v/v) nonessential amino acids. Cells were maintained at 
37°C in a humidified atmosphere of 5% CO2 in air and sub cultured once 80% confluent. 
Semi-confluent cell monolayers were sub cultured every 4 days using 0.25% trypsin 
containing 0.537 mM EDTA. HepG2 cells were grown in Minimum Essential Medium 
(MEM) containing Earl’s salts and 10% (v/v) heat inactivated fetal bovine serum under the 
similar conditions. 
 
Plasmid Preparation and Cell Transfection 
Plasmid expression vectors were constructed using standard protocols. We obtained 
human CYP3A4 cDNA (NM_017460.3) insert as 10 µg transfection-ready plasmid (
 pCMV6-XL4- CYP3A4) from Origene Technologies. The gene from the plasmid was 
then sub cloned into a vector containing neomycin resistance gene (pCMV-Neo) for 
mammalian selection necessary for stable transfection. The reconstituted plasmid was 
transfected using Lipofectamine™ 2000 Transfection Reagent (Carlsbad, CA). CYP3A4-Neo 
was introduced into HEPG2 cells according to manufacturer instructions. Briefly, cells were 
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plated 1 day before the transfection in T-75 flasks or 35-mm tissue culture plates at an 
appropriate cell density. Once 70-80 % confluent, plasmid was transfected in complete 
growth medium without a selection agent. Seventy-two hrs post transfection, cells were sub 
cultured (1:10 ratio) and grown in the medium containing selection agent, G418 at a 
concentration of 400 μg/mL. Cells were maintained in the selection medium for about 2-3 
weeks with fresh medium added every 24 hrs. Once confluent, cells were sub cultured again 
and plated as per the required experiments. 
 
Cell Cytotoxicity Assay 
MTT assay is a very sensitive cell viability assay and was performed as reported 
earlier 
182-183. Reagents were prepared as per manufacturer’s protocol. Viability assay was 
carried out in 96-well plates. Transfections were performed in scaled down manner exactly 
like in the T-75 flasks described earlier. Following the transfection, cells were washed once 
with warm PBS and then replaced with 100 μL of fresh warm PBS in each well. Cells were 
incubated in a humidified 5% CO2 atmosphere for a period of 48 h to evaluate the cytotoxic 
effects. The commercial assay used (CellTiter 96 AQueous Non-radioactive Cell 
Proliferation Assay Kit) constitutes a colorimetric method for determining the number of 
proliferating cells in culture. Cell viability was measured as the rate of fluorescent metabolite 
production (color formation) over the course of the reaction which is proportional to number 
of viable cells present. Color determination was measured at 485 nm (reference at 590 nm) 
using a 96-well microtiter plate reader (SpectraFluor Plus; Tecan, Maennedorf, Switzerland). 
For optimization of selection of selection media concentration, the non-transfected 
cells were grown in 96 well plates and treated post confluence for 72 hrs with different 
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concentrations of G418 (neomycin) containing media. Same kit using similar protocol was 
used to determine the percentage viable cells. Cells exposed to media not containing 
neomycin were used as control. 
 
Reverse Transcription 
Total RNA was isolated from cells using Trizol-LS® reagent according to 
manufacturer’s instructions. RNA was quantified by UV absorbance at 260 nm. Briefly, 1 µg 
of total RNA was mixed with 2 µl of oligo dT15 primer and denatured at 70 
o
C for 10 
minutes. After denaturation, it was reverse transcribed using 1 µL (10 units) per reaction 
mixture of MMLV Reverse Transcriptase (Promega, Madison, WI).  
 
Quantitative Real Time PCR 
Real-time PCR was conducted using an ABI 5700 GeneAmp Sequence Detection 
System (Perkin – Elmer, Applied Biosystems, Foster City, CA) capable of detecting 
fluorescence between 500 nm to 660 nm and Roche - LightCycler® 480 System. Primers 
were designed using OligoPerfect™ Designer (Invitrogen Corp. Carlsbad, CA). All the 
primers were designed such that the amplicons generated will be 100-150 bp long to increase 
the efficiency of simultaneous amplification of target and reference genes (Table 9). The 
PCR mixture has a final volume of 40 μL and contains the relevant template cDNA, 250 nM 
each of forward and reverse primers for gene of interest, 1X Mg free PCR buffer (Promega), 
3.75 mM MgCl2, 0.025U Taq Polymerase (Promega), 200 μM dNTPs, 1X ROX reference 
dye and 1X SYBR Green (Invitrogen). The specificity of the target amplicon was tested by 
melting curve analysis
184-185
. Quantitation was carried out using comparative Ct method. 
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Samples for real-time PCR were prepared in triplicate. Quantitative values were 
obtained above the threshold PCR cycle number (Ct) at which the increase in signal 
associated with an exponential growth for PCR products is detected. The relative mRNA 
levels in each sample were normalized according to the expression levels of GAPDH/β-actin. 
For these studies, initial experiments were carried to make sure that the target and 
GAPDH/β-actin genes were amplified with equal efficiencies. An induction ratio 
(treated/untreated) was determined from the relative expression levels of the target gene 
using equation 12: 
2
-ΔCt
 (ΔCt = Cttarget gene– CtGAPDH)
38…………………………………………………….Eq 12. 
 
Table 9. Real time PCR primers for CYP3A4 
 Sequence (5'->3') Template Length Tm GC% 
Forward GCACCATTAACTCCTCCTGAGCT 1890-1912 23 56.27 52.17 
Reverse AGTTCTGACAAAGGCCCCACG 2187-2167 21 56.96 57.14 
 
Immunoblotting 
Confluent cells grown on T-75 flask (75 cm
2
 growth area) were washed twice with 
PBS and harvested with a cell scraper in 5 mL of PBS. Cell suspension was centrifuged at 
1500 rpm for 10 minutes and the pellet was re-suspended in freshly prepared lysis buffer 
(PBS containing 0.1% NP40 and protease inhibitor cocktail) for 15 minutes on ice. The cells 
were first ultrasonicated for 30 s and then centrifuged at 12000 rpm for 10 minutes at 4 
o
C. 
Total protein lysate was collected and stored at -80 
o
C, until used. Protein content was 
determined using Bradford method (Bio-Rad Protein Estimation Kit, Hercules, CA). The 
proteins (20 μg/lane) were then separated on ready-made Novex® 8-16% Tris-bis Gels 
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(Invitrogen, Carlsband, CA) for 2 hrs at 120 V. Proteins were then transferred onto PVDF 
membranes for 2.5 hrs at 30V on ice using standard techniques. The blot was incubated in 
freshly prepared blocking buffer (3% w/v BSA and 5% nonfat dry milk in phosphate 
buffered saline) for overnight at room temperature. It was then probed with antibody specific 
to CYP3A4 (Xenotech LLC, Kansas City, KS) at 37 
o
C for 2-3 hrs. Following five 10-minute 
washes in PBST (Phosphate buffered saline + 0.1% Tween 20), the blots were probed with 
secondary antibody in PBST (1:2000 anti-mouse IgG-HRP). The blots were finally washed 
three times with PBST and then subjected to enhanced chemiluminescence using 
SuperSignal West Dura Kit (Pierce Biotechnology, Rockford, IL) and visualized by 
ChemiImager 8900 digital imaging system (Alpha Innotech, San Leandro, CA). The images 
of immunoreactive staining were measured and analyzed by AlphaEase software (Alpha 
Innotech). 
 
VIVID Assay 
CYP3A4 activity in HEPG2-CYP3A4 cells was assayed using the VIVID™ CYP3A4 
Red Substrate (Invitrogen), which was prepared as a 20mM stock solution in acetonitrile. 
Following transfection, the assay medium was removed and cells were washed once with 
warm PBS. Reagents were added according to the manufacturer’s protocol. Fluorescent 
readings were monitored kinetically at 37°C over a period of 30 minutes using a 96 well 
plate reader at an excitation wavelength of 530 nm and an emission wavelength of 585 nm. 
Activity was measured as the rate of fluorescent metabolite production from the metabolism 
of a Vivid® CYP450 substrate over the course of the reaction. 
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Cellular Transport Studies 
Transwell diffusion system was used for these studies. Prior to the experiment, 
MDCK based cell monolayers grown on the Transwell™inserts were rinsed with Dulbecco’s 
Phosphate Buffered Saline (DPBS) and incubated at 37 
o
C. Transfected HEPG2-CYP3A4 
were grown separately for 10 day were rinsed with Dulbecco’s Phosphate Buffered Saline 
(DPBS) and incubated at 37oC. Prior to drug incubation, the transwell inserts were placed in 
wells containing HEPG2-CYP3A4 cells. Drug solutions (Lopinavir alone and in combination 
with Ketoconazole) in DPBS (pH 7.4) were placed in the donor chamber. The receiver 
chamber was filled with DPBS. Sampling from the receiver chamber was done at 
predetermined time intervals and fresh DPBS solution was replaced to maintain sink 
conditions in receiver chamber. The samples were then analyzed by LC/MS/MS. All 
experiments are performed at 37
o
C. The effective permeability (cm/sec) was determined 
using the following Equation 13: 
  
     
       
……………………………………………………………………………Eq. 13. 
Where, P is the permeability in cm/sec, dC/dt is the slope of plot of concentration (nmoles) 
versus time (min), C is the concentration of drug (nmoles/ cm
3
), A is the surface area of the 
chamber (cm
2
), and V is the volume of each half-chamber (cm
3
). 
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Pharmacokinetic Modeling 
 
Figure 36. Pharmacokinetic model 
                                                       
Change in concentration of the parent drug in various compartments can be expressed as 
 
………………………………………..Eq. 14. 
 
……………………………………Eq. 15. 
 
……………………………….Eq. 16. 
 
………………………………….Eq. 17. 
 
Solving Equation 14 will give rise to 
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……………………………………….Eq. 18. 
If C0 in Equation 15 is substituted with the value from Equation 6, equation 3 becomes 
 
…………………………………….Eq. 19. 
 
Solving Eq. 19 for C1 results in Eq. 20 
 
……………………………………Eq. 20. 
 
If equation 20 is substituted into equation 16, it can be rewritten as 
 
……………………Eq. 21. 
 
Finally, at steady state, equation 17 becomes Eq. 22. 
……………………………….Eq. 22. 
 
Substitution of equation 22 into equation  21 gives 
……………………………Eq. 23 
 
When data from cellular transport studies is plotted as concentration vs. time, the slope of the 
resultant graph equals to dC2/dt which is being obtained from equation 23. Solving equation 
23 for C2 gives 
………………………………..Eq. 24. 
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Logarithmic transformation of Eq. 24 changes to 
………………………………Eq. 25. 
 
When ln C2 was plotted vs. time from cell transport data, k1 and k2 values can be calculated 
by solving intercept and slope values. Once, k1 and k2 values are calculated in the presence 
and absence of an inhibitor, the fold increase or decrease in concentration in the plasma can 
be predicted using the equation 26 at any particular time. 
 
………………………..Eq. 26. 
 
 
Oral Bioavailability Studies 
All the studies involving animals were carried out as per the UMKC IACUC 
regulations. Male Sprague-Dawley rats, weighing 200-300 g, were used for these studies. 
Rats were always ordered from Charles River laboratory with catheters inserted.  Briefly, rats 
were fasted overnight before the day of experiment. In these studies, lopinavir or 
lopinavir/ketoconazole at a dose of 100 mg/kg was co-administered in the form of 0.8 mL 
suspension by oral gavage. After the administration of drug combinations, blood samples 
(200 µL) were collected from the cannulated jugular vein at predetermined time intervals (0, 
15, 30, 60, 120, 180, 240, 360, 480 min). Lopinavir concentrations in the plasma were 
analyzed by LC-/MS/MS. Pharmacokinetic data analysis was carried out in WinNonlin. 
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LC/MS/MS Analysis 
Lopinavir was extracted from rat heparinized plasma by a two-step liquid/liquid 
extraction method of an ethyl acetate/hexane mixture followed by a hexane wash. Absolute 
extraction efficiency was consistent and approximately 75% over the concentration ranges 
studied. The analytes (50 μL injection) were separated on a 2.0 x 30-mm Synergi™ Polar-RP 
column (Phenomenex, Torrance, California, USA) using a formic acid/acetic acid/acetonitrile 
mobile phase with detection by selective multiple reaction monitoring (MRM) at the 
appropriate parent-to-daughter transition masses. Late-eluting interferences were eliminated 
using a low dead-volume, step-gradient flushing system. 
 
 
Results 
Optimization  of Neomycin Concentration 
To optimize the concentration of puromycin required for the selection of stably 
transfected cell lines, cell viability of HepG2 cells after growing them for 5 days in medium 
containing different concentrations of puromycin sulfate. 800 µg/mL concentration of 
neomycin in selection media was sufficient to kill all non-transfected cells (Figure 37). Cells 
exposed to media containing no neomycin was used as negative control and wells containing 
only media and no cells were used as positive control. 
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Figure 37. Cell viability of HepG2 cells after growing them for 7 days in medium 
containing different concentrations of G418 sulfate. * represents no significant 
difference from positive control, p> 0.05 
 
Cell Viability after Cell Transfections 
Since transfection reagents and foreign DNA can affect the cell survival, post 
transfection cell viability assays were conducted. Neither components of the transfection 
mixture alone nor transfection reagent and plasmid mixture produced any significant toxicity 
at the concentrations utilized (Figure 38). 
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Figure 38. Cell viability after the transfection procedure. Cells exposed for 24 hrs to 1-
Medium; 2- Plasmid only 3; Transfection reagent only and 4- Transfection reagent and 
Plasmid. * represents P value < 0.05 
 
Comparative CYP3A4 mRNA Analysis in Transfected vs Non-Transfected Cells 
Quantitative Real Time PCR was used to compare the CYP3A4 mRNA in transfected 
cell lines versus the non-transfected cell lines. HepG2 cells were used as the control cell line 
which was observed to express some amount of CYP3A4 mRNA as expected. HepG2-
CYP3A4 cells appeared to express CYP3A4 mRNA more than 6 fold compared to non 
transfected cells (Figure 39).  
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Figure 39. Comparative CYP3A4 mRNA levels normalized to GAPDH mRNA in 
HepG2 and HepG2-CYP3A4 
 
Immunoblot Analysis 
Since purpose of developing this cell line is to have functionally active CYP3A4 
protein, we carried out immunoblot analysis to establish the presence of CYP3A4 protein 
using CYP3A4 specific monoclonal antibody (Xenotech LLC). Immunoblot analysis showed 
that HepG2 cells transfected with CYP3A4 expressed significant amounts of CYP3A4 
protein (Lane 3 in Figure 40) as compared to the host cell line.  
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Figure 40. Western Blot for CYP3A3 protein 1) Molecular marker lane 2) HepG2 Cells 
3) HepG2-CYP3A4 cells 
 
Vivid™ Metabolism Assay for CYP3A4 Functional Activity 
Functional activity of CYP3A4 enzyme was then measured under the similar 
treatment conditions by VIVID CYP3A4 assay kit containing Red fluorescent substrate. 
Fluorescent metabolite formation  HepG2-CYP3A4 cell lines were almost 5 to 6 fold higher 
than host cells suggesting enhanced expression and activity of CYP3A4 (Figure 41).  
 
Figure 41. Fluorescent metabolism assay for determining CYP3A4 functional activity in 
HepG2 and HepG2-CYP3A4 cells. * represents significant difference from control with 
P value < 0.05 
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Cellular Transport Studies 
To test whether growing both the cell lines (MDCK based cells in apical chamber and 
HepG2-CYP3A4 in basal chamber) in the same system affected cell membrane integrity, 
TEER analysis was carried out. It was observed that TEER levels were reduced in the co-
culture as compared to the MDCK based cells being grown alone in transwells. Thus the cells 
were grown separately and brought together at the time of the transport. 
The pseudo permeability of lopinavir transported through the cell mono layers either in 
single or dual chamber models was calculated for all the MDCK based cell lines. It was 
observed that the permeability ratio (permeability in presence of ketoconazole vs 
permeability of lopinavir alone) was maximum in the dual chamber model with MDCK-
MDR1-CYP3A4 in the apical chamber as compared to any other models tested. Every dual 
chamber model gave higher P ratio of treated vs untreated samples when compared to their 
single chamber counterparts. 
 
Table 10. Trans epithelial electrical resistance (TEER) analysis for MCK based cells 
grown in co-culture vs individully. MMC represents MDCK-MDR1-CYP3A4 cells 
Cell Lines TEER  
(Alone) 
TEER  
(Co-Culture) 
MDCK-wt 345±24.4 276±42.8 
MDCK-MDR1 361±58.5 298±38.2 
MDCK-CYP3A4 344±34.9 230±19.8 
MMC 329±39.6 217±26.4 
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Table 11. Permeability and Pseudo permeabilities for lopinavir transport in presence 
and absence of ketoconazole carried out in various single and dual chamber models. 
Single chamber model represents only MDCK based cell line grown in apical chamber, 
Dual chamber model represents MDCK based cell line grown in apical chamber and 
the HepG2-CYP3A4 cell line grown in basal chamber. P ratio represents the ratio of 
permeability in presence of Ketaconazole vs in control. K1 and K2 represent kinetic 
parameters derived using the pharmacokinetic model. [C]inhibitor/[C]control represents 
concentration ratio calculated by new pharmacokinetic model. 
 
 
Oral Bioavailability Studies 
Oral bioavailability studies were carried out in male Sprague-Dawley rats for 
lopinavir with and without presence of ketoconazole. The ratio of Cmax in the presence of 
ketoconazole vs the absence of it was 3.5-fold. The ratio of AUC was found to increase by 
4.8-fold. 
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Table 12. Oral Pharmacokinetics of Lopinavir in rats in presence and absence of 
Ketoconazole. Ratio represents ratio of pk parameters in presence of ketoconazole vs 
the absence of it. 
PK parameters  Control  Ketoconazole  Ratio  
AUClast 
(h*ng/ml)  
1804.2 ± 
729.7  
8791.8 ± 
2079  
4.8 
Cmax (ng/ml)  556.6 ± 54  1955 ± 721  3.5  
 
Discussion 
Efflux transporters and metabolizing enzymes have both been known to play an 
essential role in the disposition of drugs in various organs of the body 
187-188
. Especially in 
the in gastrointestinal system they play a key role in reducing the bioavailability of orally 
administered substrates. Once a drug is administered orally it faces these two barriers firstly 
within the intestine. The drug that is able to bypass these barriers enters into hepatoportal 
vein from where it is taken to the liver. Here it is again subjected to high concentrations of 
metabolic enzymes. This further reduces the amount of active drug reaching into the systemic 
circulation. This first pass effect plays a major role in limiting the xenobiotic bioavailability 
through the oral route.  
Though a lot of progress has been made in the development of in vitro cell culture models to 
study the drug delivery through the oral route, none of the currently available models can 
truly mimic the complexities of the in vivo systems. Most of the currently percent cell lines 
lack the interplay between the efflux transporters and metabolizing enzymes. To overcome 
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this barrier, a dual transfected MDCK cell line was developed and proved to be a better 
model for predicting drug interactions as compared to currently prevalent ones (chapter 4). 
But this model still lacks the complexity required for true depiction of in vivo drug behavior 
as it still lacks a liver component. To include a liver component within this system, a 
Transwell
®
 based dual chamber model has been designed. In this model MDCK-MDR1-
CYP3A4 cells were grown on transwell membranes, and a liver based cell model was added 
in the basal chamber.  
Hepatocytes and microsomes have often been used as models to study the effect of 
metabolic enzymes on drugs but these suffer from some shortcomings. Hepatocytes even 
though resemble very closely to the human liver but the expression levels of metabolizing 
enzymes in them varies greatly from batch to batch and source to source. This makes it very 
difficult to replicate the data generated using this system. Liver microsomes also suffer from 
similar problems. Also microsomes have very short half-life of activity and tend to loose 
drug metabolic activity over time.  Hence a cell culture model stably expressing CYP3A4 
similar to physiological levels will be best suited for the purpose of dual chamber model. 
With this aim in mind, we developed a transfected HepG2 cell line over expressing CYP3A4. 
To optimize for the concentration of selection media required, difference 
concentrations of neomycin were exposed to the host cells. The minimum concentration of 
neomycin that causes complete cell death would be ideal for stable selection, which was 
found to be 800 µg/mL (Figure 37). Also often it has been observed that transfection 
mixtures can cause significant toxicity to the cells hence resulting in very low transfection 
efficiencies. Hence the cytotoxicity of the individual components of transfection mixture 
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alone and in combination was studied on the cells. None of the components showed any 
significant toxicities at the concentrations used.  
 Figures 39 and 40 clearly indicate transfection resulted in higher expression of CYP3A4 at 
both mRNA and protein levels. To confirm whether these protein expression levels also 
translated into increased activity of the protein, VIVID CYP activity assay was performed. 
This proprietary fluorescent substrate based assay from Invitrogen has been extensively used 
to measure the activity of CYP3A4 in in vitro systems. The assay results further confirmed 
that the protein being expressed in the transfected cell line was active (Figure 41). 
To examine how well the dual chamber model performs as compared to in vivo 
systems (Sprague dawley rats) in determining drug-drug interactions, oral bioavailability of 
lopinavir (a common substrate of P-gp and CYP3A4) were carried out. The studies were 
carried out in presence and absence of ketoconazole, a known P-gp and CYP3a4 inhibitor. As 
expected the oral bioavailability of lopinavir increased in presence of ketoconazole (AUC 
increase by 4.5-fold). Cmax which is a good indicator of altered drug absorption, also 
increased by 3.5-fold in presence of ketoconazole. Transport studies of similar combinations 
were carried out in various single and dual chamber models containing either of MDCK-WT, 
MDCK-MDR1, MDCK-CYP3A4 and MDCK-MDR1-CYP3A4. The comparison of the 
various models was done based on the effect of the interacting substance on the more 
classical parameter of cellular permeability as well as [C]inhibitor/[C]control parameter derived 
using the new pharmacokinetic model. Among all the model tested the dual chamber model 
containing MDCK-MDR1-CYP3A4 with HepG2-CYP3A4 in the vassal chamber proved to 
be the best in vitro model as the [C]inhibitor/[C]control parameter in this model came out to be 
3.07 which is closest to the Cmax ratio observed in rats. The new pharmacokinetic model 
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proved to be better indicator quantitative assessment of drug drug interactions as compared to 
cellular permeability as it values were closer to those observed in vivo. However,  the 
pharmacokinetic model was observed to work better for the dual chamber models as 
compared to the single chamber models. This is understandable as the single chamber model 
lacks the liver component which is an integral part of the pharmacokinetic model. Another 
reason why the pharmacokinetic model might be better for the dual chamber models as 
compared to permeability ratio is that the permeability measured in the case of dual chamber 
model is not a true permeability. The permeability measured in this case is more of pseudo 
permeability as the flux-based permeability calculations do not take into account the added 
effect of the basal chamber on the drug concentrations measured. Permeability ratio was a 
better indicator of the drug interactions when only the intestinal component is present in the 
model. 
 
Conclusion 
A dual chamber model containing both an intestinal component and a liver 
component has been developed. This new model is closer to the in vivo animal models for 
studying drug interactions as it contains the major barriers present in oral absorption such as 
efflux metabolism interplay as well as first pass metabolic effect. A pharmacokinetic model 
was also developed and was compared to the classical parameter cellular permeability in its 
efficiency to better predict drug interactions occurring upon oral administration of drugs.  
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CHAPTER 7 
 
BINARY AND TERNARY COMBINATIONS OF ANTI-HIV PROTEASE INHIBITOR: 
EFFECT ON GENE/PROTEIN EXPRESSION AND FUNCTIONAL ACTIVITY OF 
CYP3A4 AND EFFLUX TRANSPORTERS 
 
Rationale  
The introduction of highly active antiretroviral therapy (HAART) diminished the 
mortality rate of human immunodeficiency virus (HIV)-infected individuals besides a greater 
improvement in the quality of life. HIV protease inhibitors (PIs), which are potent 
antiretroviral agents still remains a vital constituent of highly active antiretroviral therapy 
(HAART). PIs prevent viral replication by inhibiting the activity of HIV-1 protease, 
an enzyme used by the viruses to cleave nascent proteins for final assembly of new virions. 
Several PIs and their combinations are widely indicated in the treatment of AIDS comprising 
a multi-drug therapy regimen owing to the risk of developing drug-resistant mutated viruses. 
However, treatment options vary with individuals and remain very complex. Multi-drug 
therapy is often associated with severe drug-drug interactions leading to potential adverse 
reactions ultimately leading to treatment failure
215-216
. These effects are mainly attributed to 
the development of viral
217
 and cellular resistance
218-219
. Medications alone or in 
combinations indicated in the treatment of AIDS are usually administered orally and are 
absorbed through gastrointestinal tract. Oral administration achieves relatively high 
concentrations of drugs exposed to the intestinal lumen causing potential drug-drug 
interactions.   
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The bioavailability of protease inhibitor combinations following oral administration is 
severely affected by their ability to either inhibit or induce the activity/expression of efflux 
pumps and metabolizing enzymes. The intestine is a site of expression of CYP450s and 
multiple efflux transporters. Efflux pumps i.e. P-glycoprotein (P-gp), multidrug resistance-
associated protein (MRP), and breast cancer resistant protein (BCRP) along with 
metabolizing enzyme cytochrome P450 (CYP) have been reported to be responsible for this 
alteration in bioavailability due to altered pharmacokinetics
220-222
. This further leads to 
suboptimal drug concentrations in plasma and poor penetration into the intracellular 
compartment, and causing reduced antiviral activity
223
.  
In general, drug-drug interactions arise when the disposition of one drug is altered by 
the other
215-216
. These interactions may generate additive, synergistic, or antagonistic effects 
depending on the combinations. Particularly, all protease inhibitors are good substrates of 
efflux proteins and metabolizing enzymes which could be the root cause for many of their 
drug–drug interactions. Hence during therapy clinicians are often required to adjust dosage 
owing to the PIs being substrates, inducers or inhibitors of P-gp and/or CYP. Appropriate 
dose adjustment or choice of a relatively safer combination can lead to better therapeutic 
efficacy without causing toxicity. The drug combination may have different pharmacokinetic 
interaction when co-administered in short term. But different combinations may produce 
different extent of efflux transporter and metabolizing enzyme induction when co-
administered for extended periods of time. Thus, to date many of the existing interactions 
when conducted clinically turn out to be very expensive, often inconclusive with results that 
are difficult to predict. Delineation of drug-drug interactions through clinical 
pharmacokinetic studies involves substantial cost, time and exposing human volunteers with 
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a high degree of risk. Therefore, there is a severe need to delineate drug-drug interactions 
among various protease inhibitors in vitro to predict a priori clinical drug interactions. 
However, lack of a well characterized cell line model to examine the expression of 
efflux transporters and metabolizing enzymes still poses a challenge in predicting in vivo 
drug-drug interactions. Though not well characterized, LS-180 cells have been employed to 
study induction of these transporters because of the higher, natural abundance of PXR in LS-
180 compared to Caco2 cells 
224-225
. Since the efflux proteins and metabolizing enzymes 
work in tandem to keep the xenobiotics out of the cells, the effect of the binary and ternary 
combinations of PIs on these proteins is necessary to prevent potential drug interactions and 
therapy failures. A large number of binary and ternary combinations of drugs can be studied 
together for their induction potential and a theoretical list of possibly safe clinical 
combinations of protease inhibitors can be generated. Therefore, the objective of the present 
study was to observe the effect of binary and ternary combinations of anti HIV protease 
inhibitors (PIs) on the expression of efflux transporters (P-gp, MRP-2 and BCRP) and 
metabolizing enzyme (CYP3A4) in model intestinal cell line (LS-180). This study is 
anticipated to provide a database for clinicians in selecting drug combinations to allow for 
better therapy with minimal side effects. 
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Materials and Methods 
Materials 
Protease inhibitors amprenavir, saquinavir, and lopinavir were generous gifts from 
GlaxoSmithKline, Roche and Abbott Laboratories respectively. Indinavir was purchased 
from Fisher Scientific. LS-180 cells were obtained from American Type Culture Collection 
(ATCC) (Manassas, VA). [
14
C] Erythromycin (specific activity: 51.3 mCi/mmol) was 
procured from Moravek Biochemicals (Brea, CA, USA). TrypLE™ Express, Dulbecco’s 
modified Eagle’s medium (DMEM), Vivid® CYP450 Screening Kit and ATP determination 
kit were obtained from Invitrogen (Carlsbad, CA, USA). OligodT, dNTP, MgCl2, M-MLV 
Reverse Transcriptase and CellTiter 96® Non-Radioactive Cell Proliferation Assay (MTT) 
were purchased from Promega Corporation (Madison, WI, USA). Light Cycler 480
®
 SYBR I 
Green Master Mix was obtained from Roche Applied Science (Indianapolis, IN, USA). Fetal 
bovine serum (FBS) was purchased from Atlanta Biologicals (Lawrenceville, GA, USA). 
Culture flasks (75cm
2
 growth area), 12-well plates (3.8cm
2
 growth area per well), and 96-
well plates (0.32cm
2 
growth area per well) were purchased from Corning Costar Corp. 
(Cambridge, MA, USA). All other chemicals were products of commercial grade and were 
purchased from Sigma Chemicals (St. Louis, MO, USA) and Fisher Scientific.   
 
Cell culture 
LS-180 cells have been employed for all the molecular expression and functional 
activity studies. Cells were cultured in T-75 flasks at 37 
O
C in a humidified atmosphere using 
5% CO2 and were maintained with DMEM medium supplemented with 10% fetal bovine 
serum (heat inactivated), 1% nonessential amino acids, 20mM HEPES, 29mM sodium 
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bicarbonate and 100µg/ml of penicillin and streptomycin each. The medium was changed 
every alternate day. Cells were allowed to reach 80–90% confluence which was confirmed 
with a microscope and then passaged using TrypLE™ Express solution. Cells were seeded at 
a density of 250,000 cells/well in 12-well tissue culture treated plastic plates and at a density 
of 10,000 cells/well in 96-well plates. These cells were then allowed to grow for 5–7 days 
and used for further studies.  
 
Preparation of drug solutions and drug treatment on LS-180 cells 
Individual protease inhibitor stocks were prepared in DMSO and sterile filtered 
through 0.22µm filters. Medium containing drugs either individually or for binary and 
ternary combinations were then prepared by spiking appropriate amounts from the respective 
stocks just before initiating the treatment. Cells were treated for 5 consecutive days with the 
following drugs alone and in combinations (binary and ternary combinations used are 
summarized in scheme 1): A (Amprenavir), I (Indinavir), S (Saquinavir), L (Lopinavir), AI 
(Amprenavir + Indinavir), AS (Amprenavir + Saquinavir), LI (Lopinavir + Indinavir), SL 
(Saquinavir + Lopinavir), AL (Amprenavir + Lopinavir), ALI (Amprenavir + Lopinavir + 
Indinavir), ASI (Amprenavir + Saquinavir + Indinavir), ASL (Amprenavir + Saquinavir + 
Lopinavir), SLI (Saquinavir + Lopinavir + Indinavir). Medium containing drugs was changed 
every day in all the studies performed. The final concentration of DMSO in all the drug 
solutions did not exceed 0.5% v/v. [14C] Erythromycin was selected as a model substrate to 
study MDR1 and MRP2 mediated efflux
131-132, 158
.  
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Figure 42. Scheme of PIs and their combinations used for treatment of LS180 cells 
 
Quantitative Gene Expression Analysis Using Real Time RT-PCR 
Total RNA was isolated from treated cells using Trizol
®
 reagent (Invitrogen) 
according to manufacturer’s instructions. RNA concentration was quantified by Nanodrop 
(Thermo Fisher Scientific, Wilmington, DE, USA).  Two µg of total RNA was added to 1.25 
µL of oligo dT primer and denatured at 70
o
C for 10 minutes. After denaturation, it was 
reverse transcribed using M-MLV Reverse Transcriptase. Quantitative real-time PCR was 
conducted using Lightcycler SYBR-green technology (Roche) using cDNA equivalent to 80 
ng of RNA. PCR products were subjected to a melting-curve analysis to confirm the PCR 
139 
 
specificity. Primers were designed using PRIMER BLAST tool through PUBMED. All the 
primers were designed such that the amplicons generated will be 50-150 bp long to increase 
the efficiency of simultaneous amplification of target and reference genes. The specificity of 
the target amplicon was tested by melting curve analysis. The primer sequences are 
summarized in Table 1. Quantitative values were obtained above the threshold PCR cycle 
number (Ct) at which the increase in signal associated with an exponential growth for PCR 
products is detected. The relative mRNA levels in each sample were normalized according to 
the expression levels of GAPDH which was used as an internal control. Quantitative real-
time PCR was carried out to study the alteration in the expression of metabolizing enzyme 
(CYP3A4) and efflux transporters (P-gp, MRP-2 and BCRP) and nuclear hormone receptors 
(PXR) post treatment with PI combinations in LS-180 cells. Induction levels of each test 
gene were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), according to 
the following formula:  
CTTest Gene–CTGAPDH  =ΔCT ………………………………………………………………Eq. 
27 
Thereafter, the relative mRNA induction levels of each gene were calculated using 
the ΔΔCT method:  
ΔCT Test Gene–ΔCTTest Gene in DMSO control = ΔΔCTTest Gene ………………………………….Eq. 28  
The fold changes of mRNA levels were expressed as the relative expression (2
–ΔΔCT
)
225
. 
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Table 13. Real time PCR primers 
GAPDH Sequence (5'->3') Template Length Tm GC% 
Forward AACAGCGACACCCACTCCTC 961-980 20 56.26 60 
Reverse ACCACCCTGTTGCTGTAGCC 1076-1057 20 56.5 60 
P-gp 
     Forward GAAGCCAGAACATTCCTCCTGGAA 101-124 24 56.6 50 
Reverse AGCCGCTACTCGAATGAGCTC 297-277 21 56.5 57.14 
MRP2 
     Forward GGTCATCCTTTACGGAGAACATCA Sep-32 24 54.44 45.83 
Reverse GGACTGCGTCTGGAACGAAG 132-113 20 55.35 60 
BCRP 
     Forward CCGCCACTCCCACTGAGATT 226-245 20 56.01 60 
Reverse CTCGGAGGCAGCGCTTTAAC 419-400 20 56.04 60 
CYP3A4 
     Forward GCACCATTAACTCCTCCTGAGCT 1890-1912 23 56.27 52.17 
Reverse AGTTCTGACAAAGGCCCCACG 2187-2167 21 56.96 57.14 
 
 
Immunoblotting 
For western blot analysis, treated cells grown on T-75 flask (75 cm
2 
growth area) 
were washed twice with PBS and harvested with a cell scraper in 5 mL of PBS. Cell 
suspension was centrifuged at 1500 rpm for 10 minutes and the pellet was re-suspended in 
freshly prepared lysis buffer (PBS containing 3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM 
KCl, 135 mM NaCl, 1% Triton X-100 and protease inhibitor cocktail maintained at pH 7.4) 
for 15-20 min on ice. Upon ultrasonication, the concentration of the protein lysate was 
measured using Bio-Rad protein estimation kit using bovine serum albumin (BSA) as the 
standard. Poly Acrylamide Gel Electrophoresis (PAGE) was run with proteins (50 μg/lane) 
which were separated on NuPAGE 4-12% Bis-Tris Gel (Invitrogen, Carlsband, CA) for 2 hrs 
at 120 V. Protein transfer was then carried onto PVDF membrane at 20 V for 1 h 40 min on 
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ice following standard practices. Immediately after transfer, the blot was blocked overnight at 
room temperature in 5 % Non-Fat Dry Milk and 0.25 % BSA prepared in 0.05 M Tris 
buffered saline (Sigma, St. Louis, MO) with 0.5% Tween 20 maintained at pH 8. After an 
immediate wash for 30 sec, the blot was exposed to primary antibody (CYP3A4 or P-gp) 
(abcam, Cambridge, MA, USA) at 37
0
C for 4 hours (dilution - 1:1000).  After 4 h, five 
washes were given for 6 min each in TBST. The blot was then probed with secondary 
antibody-goat anti rabbit HRP conjugate (1:10,000 dilution) (Santa Cruz Biotechnology, Inc., 
CA, USA). β-actin antibody at 1:1000 dilution (Sigma, St. Louis, MO) served as positive 
control. The blots were finally washed five times for 7 min each with TBST and then 
exposed to enhanced chemiluminescence using SuperSignal West Pico Chemiluminescent 
Substrate (Pierce Biotechnology, Thermo Scientific, Rockford, IL) and visualized by 
ChemiImager 8900 digital imaging system (Alpha Innotech, San Leandro, CA). 
 
VIVID™ Assay 
Functional activity of metabolizing enzyme (CYP3A4) in LS-180 treated cells was 
assayed using VIVID™ CYP3A4 Red Substrate (Invitrogen), which was prepared as a 
20mM stock solution in acetonitrile. Briefly, cells were plated in 96 wells and treated as 
described earlier. After 5 days of treatment, CYP3A4 activity assay was performed after 
lysing the cells and reagents were added according to the manufacturer’s protocol. 
Fluorescent readings were monitored kinetically at 37°C over a period of 30 minutes using a 
96 well plate reader (SpectraFluor Plus, Maennedorf, Switzerland) at an excitation 
wavelength of 530 nm and an emission wavelength of 585 nm. Activity was measured as the 
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rate of fluorescent metabolite production from the metabolism of a Vivid® CYP450 substrate 
over the course of the reaction for all the combinations tested. 
 
Uptake studies 
Uptake studies were performed according a previously published procedure 
158
 to 
correlate the gene expression levels to that of functional activity. Briefly, cells were plated in 
12-well tissue culture treated plates and treatment was initiated every day. Upon terminating 
treatment  after 5 days, medium containing drugs was aspirated from wells and cells were 
washed (3× 10 min) with 2 mL of Dulbecco’s phosphate-buffered saline (DPBS) containing 
130 mM NaCl, 2.5 mM KCl, 7.5 mM Na2HPO4, 1.5 mM KH2PO4, 1 mM CaCl2, 0.5 mM 
MgSO4, 5 mM glucose, and 20 mM HEPES at pH 7.4. Then 1 mL of DPBS containing 0.25 
µCi/mL of [
14
C] erythromycin was added to the cells in each well and incubated at 37 
o
C for 
30 min. Then, solutions were removed and uptake was terminated with ice-cold stop solution 
(200 mM KCl and 2 mM HEPES). Later, cells were lysed overnight at room temperature 
with 1 mL of 0.1% (v/v) Triton-X in 0.3 N sodium hydroxide solution. Aliquots (500 µl) of 
the cell lysate were then added to scintillation vials containing 3 mL of scintillation cocktail 
(Fisher Scientific, Fair Lawn, NJ) and radioactivity was measured with a scintillation counter 
(Model LS-6500; Beckman Counter, Fullerton, CA) with an efficiency of 95 % to measure 
[
14
C] compounds. Uptake in each well was normalized to protein content, estimated by the 
Bio-Rad protein estimation kit using bovine serum albumin (BSA) as the standard. 
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Cell Viability Assay 
Cell viability assay was performed to examine the toxicity of PIs and their binary and 
ternary combinations tested in this study. For this assay CellTiter 96 AQueous Non-
radioactive Cell Proliferation Assay Kit (Promega, Madison, WI) was used which constitutes 
a colorimetric method for determining the number of viable cells in culture. Briefly, cells 
were seeded onto 96-well plates for the assay and the treatment was initiated. 100µL of 
respective drug solution/combinations was added to the wells to evaluate the cytotoxic effect 
of the combinations tested. Medium was replaced by freshly prepared drug solutions every 
day and the assay was performed according to manufacturer’s directions. Cell viability was 
measured as the rate of fluorescent metabolite production (color formation) over the course 
of the reaction which is proportional to number of viable cells present. Color determination 
(absorbance) was then measured at 485nm (reference at 590nm) using a 96-well microtiter 
plate reader (SpectraFluor Plus, Maennedorf, Switzerland). 
 
ATP Determination Assay 
The cells at a density of 10,000/well were seeded in 96-well plates and treatment was 
initiated with 100µL of respective PIs and their binary and ternary combinations. 
Subsequently, upon termination of the treatment after 5 days, medium containing drug 
solutions was removed and the cells were washed with DPBS (3 x 10 min). Lysis solution 
(100 µL) was then added and the lysate was further utilized for the quantitative detection of 
ATP using ATP Determination Kit (Molecular Probes, Invitrogen) following manufacturer’s 
instructions 2,4-DNP (1 mM) served as ATP inhibitor. Luminescence was then measured 
using a microtiter plate reader (SpectraFluor Plus, Maennedorf, Switzerland) and it was 
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normalized to protein content. It was estimated by the Bio-Rad protein estimation kit using 
bovine serum albumin (BSA) as the standard. 
 
Results 
Expression of CYP3A4 and Efflux Transporters mRNA in LS-180 Cells 
Real Time-PCR (qRT-PCR) analysis was carried out to study the alteration in the 
expression of CYP3A4 and efflux transporters (P-gp, MRP-2 and BCRP) mRNA post 
treatment with PI combinations in LS-180 cells. Binary and ternary combinations of protease 
inhibitors appeared to modulate the expression of efflux transporters and CYP3A4 in a 
considerable manner. Unlike the individual PIs their binary combinations showed much 
greater induction of the gene expression (5–15 fold) which was not found to be as 
pronounced in the presence of their ternary combinations (1-4 fold). This trend was observed 
to be similar for all the mRNA tested (Figure 43 A-D). The fold induction of for each drug 
combination and gene was compared to cells exposed to DMSO. 
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Figure 43. Relative fold mRNA induction of A. CYP3A4, B. MRP2, C. P-gp, D. BCRP 
post treatment with PIs in LS180 cells. n=4, * represents P value < 0.05, ** represents P 
value <0.01 
 
Immunoblot Analysis for CYP3A4 and P-gp  
To confirm whether the gene expression studies translated into protein levels a 
western blot was performed. To limit the number of samples for this experiment, only 
combinations with maximal and minimal induction levels were chosen i.e. A, I, L, AI, AL 
and ALI. Protein levels were found to correlate well with the gene expression levels (Figure 
44). 
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Figure 44. Westernblot analysis of certain combinations of LS180 cells when trated with 
certain PI combination. β-actin was used as internal standard. 
 
Expression of Nuclear Hormone Receptors mRNA in LS-180 Cells 
Quantitative RT-PCR analysis was carried out to study the alteration in the expression 
of nuclear hormone receptor (PXR) mRNA post treatment with PI combinations in LS-180 
cells. This was done to study if any correlation existed between induction of nuclear hormone 
receptors and the alteration in the gene expression of efflux transporters and metabolizing 
enzymes. The induction levels of PXR corroborated well with the expression levels of 
CYP3A4 and efflux transporters as observed in gene expression studies. Binary combinations 
showed much greater induction of the gene expression of PXR when compared to individual 
PIs or their ternary combinations (Figure 45). Similar to what has been observed in 
previously published reports, CAR was found to be non inducible in LS-180 cells (data not 
shown). 
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Figure 45. Relative fold mRNA induction of PXR post treatment with PIs in LS180 
cells. n=4, * represents P value < 0.05, ** represents P value <0.01 
 
VIVID™ Metabolism Assay for CYP3A4 Functional Activity 
To study whether the alteration in mRNA expression translates into functional 
activity, the activity of CYP3A4 enzyme was then measured under the similar treatment 
conditions by VIVID™ CYP3A4 assay kit containing red fluorescent substrate. Fluorescent 
metabolite formation was found to be significantly higher in cells treated with binary 
combinations of PIs (with maximum activity observed in AS combination) as compared to 
the individual PIs or their ternary combinations (Figure 46). Even though a multifold increase 
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in the mRNA levels was observed upon treatment it did not translate into similar levels of 
functional activity but the trend remained similar. 
 
Figure 46. Vivid assay for CYP3A4 activity in LS180 cells post PI treatment. n=8. * 
represents P value < 0.05 
 
 
[
14
C] Erythromycin Uptake in LS-180 Cells  
Erythromycin being a known substrate of P-gp and MRP-2 
158
, [
14
C] Erythromycin 
uptake was performed in the cells treated with various PI combinations. Significant reduction 
in erythromycin uptake was observed in cells treated with binary combinations of PIs. There 
was no significant reduction in uptake upon treatment with either individual or ternary 
combinations of PIs (except in case of amprenavir alone and the ternary combination of 
saquinavir, lopinavir and indinavir) (Figure 47).  
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Figure 47. Percentage uptake of [14C] erythromycin in LS180 cells post PI treatment. * 
represents P value < 0.05, ** represents P value <0.01 
 
Cell Viability (MTT) Assay  
MTT assay was performed to study the cytotoxicity of individual PIs and their 
combinations. None of the combinations (except binary combination SL and ternary 
combination SLI) produced any significant toxicity at the concentrations utilized (Figure 48) 
 
 
Figure 48. Cell viability (MTT) assay carried out on LS180 cells post PI treatment. n=8, 
* represents P value < 0.05 
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ATP Activity Assay in LS-180 Cells  
ATP activity assay was performed in LS-180 cells post PI combination treatment. 
There was no significant increase in ATP activity upon treatment with either individual or 
binary combinations of PIs when compared to vehicle control. There was some increase in 
ATP activity in cells treated with some ternary combinations (ALI, ASI, ASL) (Figure 49). 
The ATP activity trend did not correlate well with the efflux transporter activity observed in 
previous studies. 
 
 
Figure 49.  ATP activity assay in LS180 cells post PI treatment. n=8, * represents P 
value < 0.05 
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Discussion 
LS-180 cells have been shown to be a good model for predicting long term drug-drug 
interactions based on efflux transporter and metabolizing enzyme induction 
226-227
. Our long 
term goal is to further validate it as a model cell line for studying potential drug interactions 
for chronically dosed drugs. Previous studies have shown that individual PIs are inducers of 
metabolizing enzymes and efflux transporters 
225-226
 and that LS-180 cells can be effectively 
used to study this induction potential. Due to high occurrence of drug resistance and to 
reduce potential therapeutic failure anti-retroviral drugs including protease inhibitors are 
generally given in binary or ternary combinations. Though the induction potential of 
individual PIs for various efflux transporters and metabolizing enzymes may be known, they 
can show altered induction capability when given in various combinations. This is the first 
time that binary and ternary combinations of protease inhibitors are being studied for their 
effect on the expression and activity of various efflux transporters and metabolizing 
enzymes. 
Protease inhibitors have been shown to induce multiple enzymes of the cytochrome 
P-450 family 
228-229
. For these studies only CYP3A4 expression and activity was tested as it 
has already been reported that LS-180 cells do not show significant induction of other CYP 
enzymes even in presence of known inducers 
225
. Though A, S, L, I were all previously 
reported to be inducers of CYP3A4 at 10 µM concentration in LS-180 cells, only A and S 
showed significant induction. All five binary combinations tested in our studies showed 
much higher induction of CYP3A4 as compared to the individual PIs. Though LI 
combination showed more than 5-fold induction, it was still the weakest inducer among all 
binary combinations tested. AI combination showed the highest induction potential among all 
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the combinations studied.  Though all ternary combinations showed 3 to 5 fold induction, 
surprisingly the induction potential for all ternary combinations was relatively lesser than that 
for binary combinations (Figure 43A). 
Among all the binary combinations tested AI, AL and LI showed significant 
induction for all of the studied efflux transporters out of which AI combination was found to 
be the most potent inducer (Figure 43B-D). Surprisingly none of the individual PIs or their 
ternary combinations demonstrate any significant induction of MRP2 in LS-180 cells, yet all 
of the binary combinations (except AS) showed very high induction potential for MRP2 
(Figure 43B).  At the concentration tested, A showed very high induction of P-gp along with 
the three previously described binary combinations (Figure 43C).  None of the other binary 
and ternary combinations showed any induction or inhibition.  In case of BCRP, A along 
with ternary combination of SLI and along with AI, AL and LI showed significant induction 
and L showed inhibition at the tested concentrations (Figure 43D).  
Sometimes induction at genetic level does not translate into higher levels of protein 
expression. To check whether these induction levels corroborate with protein levels, the 
samples with extreme levels of induction were tested for protein expression (CYP3A4 and P-
gp). The trend observed in the blots matched with those observed in the gene expression 
studies. Hence 4 day treatment in LS-180 cells is sufficient time for achieving induction at 
both genetic and protein levels.  
Several nuclear hormone receptors and transcriptionally mediated pathways have 
been reported to be responsible for chemically induced elevated expression of various 
proteins in response to xenobiotic exposure.  PXR and CAR have been especially reported to 
play a significant role in the regulation of expression levels of multiple efflux transporters 
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and metabolizing enzymes 
230-232
. Previous reports have shown that the expression levels of 
PXR correlates well with the expression levels of metabolizing enzymes both in vitro and in 
vivo
233
. The mRNA levels of PXR upon similar treatments with PI combinations were tested 
and the PXR induction levels were found to correlate with the induction levels of efflux 
transporters and metabolizing enzymes (Figure 45). Previous reports have suggested that LS-
180 cells may not be the best cell line to study CAR mediated induction of genes 
225
 and our 
results corroborated with this hypothesis as none of the drugs or their combinations showed 
any significant induction of CAR (data not shown) when measured with qRT-PCR. 
The mRNA expression levels even though can be a good indicator of the downstream 
protein activity but to confirm the results various metabolic as well as efflux transporter 
activity assays were carried out.  VIVID™ CYP3A4 assay is a well-known method to 
quantify the CYP3A4 activity within cells
158, 220
.  The increase in CYP activity for the treated 
cells was found to correlate well with the mRNA levels qualitatively but not quantitatively. 
The activity increase was 1.5 to 2-fold whereas the mRNA induction was 5 to 10-fold. 
Amprenavir (A) and ternary combinations of ALI and ASI did not show significant increase 
in activity (Figure 46) even though it was observed at genetic level.  
Erythromycin is a known substrate of MRP2 and P-gp and hence uptake of [
14
C] 
erythromycin was performed to study the effect of the treatment on P-gp and MRP2 activity 
levels. Even though A showed very high induction of P-gp mRNA (no effect was observed 
on MRP2 mRNA) but very little decrease in uptake of [
14
C] erythromycin was observed 
(Figure 47). All binary combinations other than SL showed significant decrease of [
14
C] 
erythromycin uptake showing similar trend to that observed in gene expression studies. Only 
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SLI showed any significant decrease in erythromycin uptake among all the ternary 
combinations tested.  
The reason for the increase in the expression and activity levels of efflux transporters 
and metabolizing enzymes from single PI treatment to binary combinations can be a direct 
additive effect of increase in molar content of drug being exposed to the cells. But a similar 
additive effect should be observed in the case of ternary combination if it is only a result of 
stoichiometry.  The reason for this discrepancy in the expression levels observed with ternary 
combinations can be a stress response due to cytotoxic effects of ternary combinations 
234-235
. 
To test this hypothesis, an MTT assay was performed to study the cytotoxic effects of all the 
combinations (Figure 48). All combinations tested were found to be non cytotoxic to the cells 
except SL and SLI. The induction of various genes observed with SLI may be attributed as a 
cellular stress response. Yet, the general lack of cytotoxicity observed with other ternary 
combinations excludes the possibility of the decrease in induction levels observed with 
ternary combinations being a stress response.  
Previous studies have shown that cell treatments that affected the ATP levels also 
resulted in altered uptake of efflux transporter substrates 
236
. To further confirm that the 
decrease in the uptake of erythromycin is due to the induction of efflux transporters and not 
because of decrease in their activity, an ATP assay was performed. None of the individual 
PIs or their binary combinations showed any significant increase in ATP activity post 
treatment (Figure 49). Hence the increase in efflux activity observed probably a result of 
increased expression and not an alteration of a cofactor activity. Slight increase in ATP 
activity was observed in three of the ternary combinations (ALI, ASI, ASL) none of which 
had shown any increased efflux post treatment. 
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The induction of gene expression might have been a simple additive effect due to increased 
molar quantities of protease inhibitors. But if this was the case then the ternary combinations 
should show higher induction than the binary combinations. Docking studies with different 
PXR agonists and antagonists using novel computational models have shown that there might 
be different binding sites present in PXR 
237-238
. The increased induction in binary 
combinations may be due to occupation of allosteric activators. The subsequent decrease of 
induction in ternary combinations maybe then due to eventual binding with exposed 
inhibitory sites. Further computational and activity based studies need to be undertaken to 
further elucidate this phenomenon.  
 
Conclusion 
This is the first time a comprehensive study has been undertaken in which the 
difference in the induction potential of binary and ternary combinations of PIs for induction 
of CYP3A4 and efflux transporter transcripts in LS-180 cells has been shown. For the first 
time it has been shown that binary combinations in general showed greater modulation of 
gene expression and functional activity CYP3A4 and efflux transporters as compared to the 
individual PIs or their ternary combinations. This induction was found to be PXR mediated. 
Since a simple additive effect is not the reason for this observed induction, further studies 
need to be performed to identify the possibility of allosteric inhibition of PXR activity in case 
of certain combinations. The cell line and techniques used can be utilized for the rapid 
screening of different drug combinations for their potential to induce efflux transporters and 
metabolizing enzymes and thus predicting potential drug interactions. 
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CHAPTER 8 
SUMMARY AND RECOMMENDATIONS 
Summary 
In the current therapeutic scenario multi-drug regimens are often employed in clinical 
situations. This co-administration of multitude of drugs often leads to pharmacokinetic and/or 
pharmacodynamic drug-drug interactions which sometimes lead to adverse drug reactions 
and treatment failures. Therefore, it becomes essential to generate substantial amount of data 
on drug-drug interactions during the initial drug development process itself of each new drug 
entity. Such data allows clinicians to design better therapies by prescribing safer drug 
combinations. But to carry out such drug interaction studies in a clinical setting is financially 
prohibitive and requires large amount of time and also puts the human volunteers at risk.  
This will, in turn, prolong the time required to bring a drug into the market and the added 
costs will make the drug more expensive. The huge number of possible interactions makes 
the process unfeasible. Therefore, broad objective of the this project was to develop, validate 
and use in vitro cell culture  models to assess drug interactions taking place at intestine and 
liver, the two major sites of drug interactions in oral drug delivery. 
Results presented in the first study utilized MDCK cells transfected with efflux 
transporters to test whether a particular drug is a substrate of those proteins. These cell lines 
proved to be highly useful for this analysis. Gatifloxacin, the drug under study suffers from 
low bioavailability as well as high occurrence of drug resistance but no mechanistic 
explanations existed for this phenomenon. By utilizing these transfected cell lines it was 
indicated that the drug interacts with P-gp and MRP2 which are often responsible for lower 
bioavailability of its substrates and also their acquired resistance. These results also 
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suggested that gatifloxacin can cause drug interactions if administered with other P-gp/MRP2 
substrates or inhibitors. 
In chapters 4 and 5, dual transfected MDCK cell lines were developed and 
characterized. These cell lines have enhanced expression of efflux transporter and 
metabolizing enzymes within the same cell line. It has been hypothesized by multiple groups 
that efflux and metabolism work in conjunction in our body to synergistically limit the 
bioavailability of xenobiotics in our body. Currently no models exist where these two 
proteins can be studied together to find out the potential mechanism behind their synergism. 
These dual transfected cell lines proved really useful in delineating the underlying 
mechanism between the synergism between efflux and metabolism. These cell lines also 
proved to be better models to predict potential pharmacokinetic drug interactions as these are 
both more accurate as well as high throughput. 
In chapter 6 a more complex in vitro model was developed which integrates an 
intestinal component as well as a liver component to simulate the first pass effect occurring 
in the body after oral administration of drug. In this model mono and dual transfected MDCK 
cell lines were plated in the apical chamber and the liver based CYP3A4 transfected HepG2 
cell line was placed in the basal chamber of a transwell. A pharmacokinetic model was also 
developed to generate pharmacokinetic parameters which can better correlate with in vivo 
pharmacokinetic parameters. The dual chamber model when used with the pharmacokinetic 
model for analysis proved to be the model with most accurate predictive power for potential 
drug interactions among all the models developed during the work on this dissertation. 
In the last study, LS180 cells were tested as potential models to predict the induction 
potential for efflux transporters and metabolizing enzymes for chronically administered drug 
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combinations. The LS180 cells proved to be a good model for predicting potential long term 
drug interactions based on PXR mediated induction of efflux transporters and metabolizing 
enzymes. These studies also showed that binary combinations can be stronger inducers as 
compared to ternary combinations of PIs. These results also indicate that PXR may have 
allosteric activation and inhibitory sites.  
In summary, the models developed during this dissertation are really useful in 
screening large number of drug combinations for potential long and short term 
pharmacokinetic drug interactions.   
                                                                          
                                                         Recommendations 
The cell lines created during the work on this dissertation are very useful in 
delineating potential drug–drug interactions. The results presented in these studies also 
enhanced our knowledge about potential mechanisms of interplay between efflux transporters 
and metabolizing enzymes. Based on the studies and results in this discussion few 
recommendations can be made to take this work further 
  Though previous generation fluoroquinolones were known to be substrates of efflux 
transporters, for the first time it was identified that gatifloxacin (a fourth generation 
fluoroquinolone) is also a substrate. Further studies using other 4
th
 generation 
fluoroquinolones (such as gemifloxacin and moxifloxacin) must also be undertaken to 
find out if it’s a common phenomenon throughout the generation. 
 For these studies the combination of two efflux transporters (P-gp and MRP2) was 
studied along with one metabolizing enzymes. Similar studies should be undertaken 
using different combinations of efflux transporters and metabolizing enzymes so as to 
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identify whether the interactions seen exist only in these isolated systems or whether 
they are more generalized phenomenon.    
 Drug classification systems such as BCS and BDDS segregate drugs based on their 
solubility and permeability characteristics. Though useful, these classification 
systems are not always that accurate in predicting drug characteristics in vivo. Since 
the models designed in this study are high throughput, drugs belonging to various 
categories of these systems can be screened on these in vitro models for validation of 
their categorization. This in turn will further validate these in vitro models as 
potential systems to screen new drug entities. 
 The induction studies carried out with LS180 cells presented interesting new facts 
about how PXR may work. Further, computer docking and PXR functional activity 
studies are also needed to be undertaken. 
  The new long term and short term interactions identified during these projects are 
needed to be tested clinically. 
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